



The role of GABAergic signalling in neurodevelopmental disorders

Xin Tang^{1,2}✉, Rudolf Jaenisch¹ and Mriganka Sur^{1,3}

Abstract | GABAergic inhibition shapes the connectivity, activity and plasticity of the brain. A series of exciting new discoveries provides compelling evidence that disruptions in a number of key facets of GABAergic inhibition have critical roles in the aetiology of neurodevelopmental disorders (NDDs). These facets include the generation, migration and survival of GABAergic neurons, the formation of GABAergic synapses and circuit connectivity, and the dynamic regulation of the efficacy of GABAergic signalling through neuronal chloride transporters. In this Review, we discuss recent work that elucidates the functions and dysfunctions of GABAergic signalling in health and disease, that uncovers the contribution of GABAergic neural circuit dysfunction to NDD aetiology and that leverages such mechanistic insights to advance precision medicine for the treatment of NDDs.

NDD risk genes

Candidate genes identified from patient populations with clinically diagnosed neurodevelopmental disorders (NDDs) in which mutations are associated with increased risk of developing NDD symptoms.

Transcription factors

Proteins that bind to specific DNA sequence motifs and regulate the transcriptional levels of target genes to determine cellular identity and function.

Neurodevelopmental disorders (NDDs) affect one in six children in the USA¹ and have a very strong genetic basis. There are many, diverse, NDDs — including fragile X syndrome (FXS), Angelman syndrome, Rett syndrome and autism spectrum disorders (ASDs). Yet, a considerable proportion of clinically identified NDD risk genes encode components of the GABAergic inhibition system, including transcription factors, GABA receptors, inhibitory synaptic proteins and chloride transporters². Genetic mutations or epigenetic perturbations that disrupt the expression of these NDD risk genes can cause profound dysfunctions in the generation, migration and survival of inhibitory neurons as well as in the connectivity, function and plasticity of inhibitory circuits.

In this article, we review studies that characterize developmental processes of the GABAergic inhibition system in normal brains, and recent work using preclinical models of NDDs to reveal the genetic, molecular, cellular and circuit bases of NDD-related impairments in GABAergic inhibition. We mostly use genetic forms of ASDs, such as Rett syndrome, as examples in this Review to reflect the large volume and extensiveness of the literature. We also discuss research that supports or challenges a prevalent hypothesis of NDD — excitation–inhibition (E/I) imbalance — and extend this hypothesis to a broader framework of imbalanced circuit homeostasis propagated by deficits in neuronal chloride transporter activity and GABAergic signalling.

Currently, very few therapeutic options are available to treat NDDs. A mechanistic understanding of GABAergic inhibitory dysfunction in NDDs may assist future development of feasible clinical solutions for diagnosis and treatment of NDDs. Here, we discuss the

genetic, molecular and brain activity markers of NDDs that may enable more accurate diagnosis of disease and a stratification of patients. We also discuss exciting emerging work that indicates converging NDD disease mechanisms — such as impairments in the expression of neuronal chloride transporters and the reduction in interneuron numbers — that could potentially be applied broadly to correct neural circuit abnormalities across multiple NDD subtypes and may assist in the development of precision medicine therapeutics.

The basics of GABAergic inhibition

During mammalian brain development, GABAergic neurons that are generated in proliferative zones migrate to target brain structures and assemble into the GABAergic signalling system. This system modulates network excitability through the phasic and tonic inhibition modes mediated by GABA receptors, and through the dynamic regulation of the transmembrane chloride gradient determined by neuronal chloride transporters. The highly dynamic GABAergic system has pivotal roles in modulating the activity and plasticity of neural networks during development and adulthood.

Building the GABAergic cell infrastructure. GABAergic interneurons, which constitute approximately 20–30% of the neurons in the cerebral cortex, originate mostly from proliferative zones that produce largely distinctive interneuron populations, including the medial ganglionic eminence (MGE), caudal ganglionic eminence (CGE), lateral ganglionic eminence and preoptic area³ (FIG. 1a).

The temporal and spatial patterns of transcription factor expression drive the cardinal specification of

¹Whitehead Institute for Biomedical Research, Cambridge, MA, USA.

²Boston Children's Hospital, Boston, MA, USA.

³Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.

✉e-mail: xin.tang@childrens.harvard.edu
<https://doi.org/10.1038/s41583-021-00443-x>

Excitation–inhibition (E/I) imbalance

Disruption in the balance between excitatory and inhibitory drives that causes either overexcitation or underexcitation of neural circuits observed in various neurodevelopmental disorder subtypes.

these interneurons. For example, MGE-derived progenitor cells in the developing mouse brain express *Nkx2-1* during the progenitor stage, followed by sequential expression of the transcription factor genes *Lhx6*, *Sox6*, *Sip1* (also known as *Zeb2*) and *Satb1*. These transcription factors coordinate changes in gene expression that determine the identity of fast-spiking interneurons that express the calcium-binding protein parvalbumin (PV) and of non-fast-spiking interneurons that contain the neuropeptide somatostatin (SST)³. By contrast, CGE-derived progenitor cells specifically express the transcription factors encoded by *Coup-tf1* (also known as *Nr2f1*) and *Coup-tf2* (also known as *Nr2f2*) and generate bipolar interneurons that express vasoactive

intestinal peptide (VIP) or multipolar interneurons that express the glycoprotein reelin (RELN)⁴. Interestingly, the *Dlx* gene family members *Dlx1*, *Dlx2*, *Dlx5* and *Dlx6* are expressed in both MGE-derived progenitors and CGE-derived progenitors⁴, indicating their indispensable roles in GABAergic neuron fate determination. Recent technological advances such as single-cell RNA sequencing⁵ as well as the directed differentiation of human stem cells⁶ and cell fate transdifferentiation⁷ are advancing our understanding of the gene regulatory logic underlying the establishment and maintenance of GABAergic neuron identity.

Interneurons generated in proliferative zones migrate tangentially to the subcortical and cortical regions,




Fig. 1 | Development of the GABAergic signalling system. a | In the mammalian brain, GABAergic interneurons are generated in proliferative regions, including the medial ganglionic eminence (MGE), the lateral ganglionic eminence (LGE), the caudal ganglionic eminence (CGE) and the preoptic area (POA), and then migrate around the lateral ventricle (LV) to the subcortical and cortical destination areas, where they undergo further specification^{8,9}. Recent advances in stem cell biology enable the generation of GABAergic neurons in vitro using directed differentiation from pluripotent stem cells (PS cells) to neural progenitor cells (NPCs), then to functional human GABAergic neurons⁶. Also, somatic cells such as fibroblasts can be transdifferentiated into GABAergic neurons through ectopic expression of transcription factors⁷. **b** | A simplified diagram showing the connectivity of the main subtypes of interneuron, including parvalbumin-expressing (PV⁺), somatostatin-expressing (SST⁺), vasoactive intestinal peptide-expressing (VIP⁺) and reelin-expressing (RELN⁺)

neurons³. The number of interneurons also undergoes dynamic changes during development as the neurons integrate into brain networks¹³. **c** | GABAergic signalling regulates neural network excitability through three main mechanisms: fast phasic inhibition mediated by synaptic GABA type A receptors (GABA_AR_s); slow tonic inhibition mediated by extrasynaptic GABA_AR_s¹⁹; and the dynamic regulation of the intracellular chloride concentration by the chloride transporters NKCC1 and KCC2, which determines the polarity and efficacy of GABAergic inhibition²⁷. **d** | GABAergic inhibition has major roles in modulating neural network oscillations⁵⁴ and brain circuit plasticity during development and in adults. The developmental plasticity window is closed in adult animals such that monocular deprivation no longer changes the eye-specific projection pattern to the visual cortex, indicated by the differently coloured stripes. Blocking GABAergic inhibition in adult animals reactivates visual cortex plasticity⁵⁴. CC, current clamp; LFP, local field potential.

Stratification of patients

Rational partitioning of patients into subgroups, based on their behavioural metrics, biomarkers and genetic information, to facilitate precise diagnosis and targeted treatment.

Precision medicine

An approach to medicine that considers the biological variabilities of each patient, such as sex, genetics and other biomarkers, for devising personalized treatment regimens.

Epigenetic factors

Modifications to the chromosome, including methylation and histone modifications, that regulate the expression level of genes without altering the primary DNA sequence.

GABA functional switch

A developmental process during which GABA action switches from excitatory to inhibitory, driven mainly by altered expression and function of the chloride transporters NKCC1 and KCC2.

where they then migrate radially into the developing cortical layers^{8,9}. The termination of interneuron migration at a final destination is determined by cellular responses to the ambient levels of GABA in the tissue: owing to low expression of the chloride exporter KCC2 (also known as the K⁺-Cl⁻ cotransporter) and high expression of the chloride importer NKCC1 (the Na⁺-K⁺-Cl⁻ cotransporter) in interneurons during this migration, the intracellular chloride concentrations are high in these cells, causing ambient GABA to elicit membrane depolarization and lead to calcium influx that promotes interneuron motility¹⁰. As the interneurons enter the cortex, KCC2 expression is upregulated, whereas NKCC1 expression is downregulated, rendering GABA inhibitory and terminating the migration of interneurons in a voltage-sensitive, calcium-dependent manner¹⁰.

After reaching their final destinations in the cortical and subcortical brain tissues, interneurons undergo further diversification that is driven by interactions between the genetic code, epigenetic factors and neural activity¹¹. The four main classes of cortical interneuron defined by the markers PV, SST, RELN and VIP each send axonal projections to target different cellular compartments of excitatory pyramidal neurons. PV⁺ cells directly target the neuronal soma of pyramidal neurons to reduce neuronal firing, whereas SST⁺ and RELN⁺ cells target mainly the distal dendrites to regulate the integration of excitatory synaptic inputs. VIP⁺ neurons, by contrast, target both SST⁺ and PV⁺ inhibitory neurons and thus mediate disinhibition of pyramidal neurons^{3,12}. These molecularly and functionally defined interneurons integrate into the developing cortex in coordination with glutamatergic neurons to establish circuit-level E/I balance^{13,14} (FIG. 1b).

Modes of GABAergic inhibition. In a fully developed brain, the GABAergic network modulates neural circuit activity through two major modes of inhibition: phasic and tonic. Phasic inhibition is mediated mainly by action potential-induced presynaptic GABA release, which triggers chloride currents passing through ligand-gated ionotropic GABA type A receptors (GABA_ARs) at postsynaptic sites to provide temporally precise inhibition that rises and decays within hundreds of milliseconds (FIG. 1c). The formation of GABAergic synapses follows two general steps. The initial contact between the presynaptic nerve terminal and postsynaptic cell is established by cell adhesion events mediated by presynaptic neurexin¹⁵ and postsynaptic neuroligin 2 (REF. 16). Then, as the presynaptic GABA release machinery matures, inhibitory synapse-specific postsynaptic scaffolding proteins, including gephyrin¹⁷ and collybistin¹⁸, anchor GABA_ARs and other proteins necessary for GABAergic synapses to function to the postsynaptic membrane.

In contrast to the rapid phasic inhibition at GABAergic synapses, tonic GABAergic inhibition is mediated mainly by extrasynaptic GABA_ARs that provide slow and persistent 'background' inhibition¹⁹. The extrasynaptic GABA_ARs typically contain $\alpha 5$ (REF. 20) or δ (REF. 21) subunits, whose expression levels are downregulated or upregulated during development, respectively²².

Such receptors can respond to very low concentrations of ambient GABA in the extrasynaptic space, including the GABA that diffuses from the synaptic cleft when it is not taken back up by GABA transporters²³ and the small amount of GABA released from astrocytes via the bestrophin 1 channel²⁴. Although the conductances of individual extrasynaptic GABA receptors are relatively small compared with those of their synaptic counterparts, tonic GABAergic inhibition plays a substantial role in the modulation of neuronal excitability owing to the wide distribution of extrasynaptic GABA_ARs and the steady integration of currents over long periods²⁵ (FIG. 1c). In addition to the ionotropic mechanisms, activation of metabotropic GABA_BRs elicits long-lasting inhibition of presynaptic glutamatergic release and postsynaptic Ca²⁺ signalling²⁶.

On top of base synaptic and extrasynaptic GABAergic signalling, one fundamental process that determines the polarity and efficacy of GABAergic signalling is the dynamic regulation of the electrochemical gradient of chloride across plasma membranes by the neuronal chloride transporters NKCC1 and KCC2 (REF. 27). NKCC1 is the main chloride importer in neurons, whereas KCC2 is the only neuronal transporter that can extrude chloride. At the early postnatal stage of mammalian brain development, KCC2 expression is low, whereas NKCC1 expression is high, leading to a high intraneuronal chloride concentration. As a result, when GABA_ARs open upon the binding of GABA, negatively charged chloride ions exit the cell and depolarize the membrane²⁸ (FIG. 1c). Notably, a depolarizing GABA action does not necessarily trigger action potential firing: the large conductance mediated by GABA_AR activation may render the membrane 'leaky' and cause shunting inhibition, such that additional excitatory inputs can no longer trigger action potentials²⁹. Therefore, the net effect of GABA-induced depolarization on the functioning of a developing brain network is context dependent.

With development, the expression of KCC2 substantially increases and NKCC1 expression decreases. As a result, the intraneuronal chloride concentration is reduced, and GABA signalling is functionally 'switched' to hyperpolarize the membrane and reduce neuronal firing²⁷. The timing of the GABA functional switch in the rodent brain is generally between the first and the second postnatal week in the cortical and hippocampal regions^{28,30}, with a few exceptions: for example, PV⁺ cells that regulate hippocampal neurogenesis in the dentate gyrus remain depolarized by GABAergic projection from the medial septum even in adult animals³¹, and GABAergic inputs onto mouse hippocampal CA3 neurons remain depolarizing throughout development³². By contrast, the GABA functional switch in humans occurs over a longer timeline. Cultured human stem cell-derived cortical excitatory neurons supported by astrocytes take 2–3 months to reach robust KCC2 expression and complete the GABA functional switch³³. In the human brain, although *SLC12A5* mRNA, which encodes KCC2 protein, is detected in certain brain regions at birth³⁴, a substantial elevation in KCC2 expression and the GABA functional switch occur in the cortex during the first postnatal year³⁵.

NKCC1 indirectly modulates the formation of both excitatory and inhibitory synapses and drives synaptic network maturation through GABA-induced depolarization and the activation of NMDA receptors^{36–38}. By contrast, KCC2 directly interacts with actin cytoskeleton-binding proteins to regulate dendritic spine morphogenesis and the function of excitatory synapses^{39–42}. In line with this, proteomics studies reveal that KCC2 has more protein-binding partners at excitatory synapses than it does at inhibitory synapses⁴³. Therefore, KCC2 is a ‘keystone’ molecule that modulates both excitation and inhibition in neurons. In summary, neuronal chloride transporters provide a ‘master switch’ to dynamically modulate the efficacy of GABAergic signalling, which, in conjunction with the number and strength of GABAergic synapses, establishes network-level balance between excitation and inhibition.

Balancing neural circuit excitation with inhibition.

Neurons assemble into functional ensembles and further incorporate into neural circuits that form the basis of the complex input–output and plastic properties of the neural network. GABAergic inhibition is central to shaping these emerging network properties, by providing a homeostatic mechanism that maintains network excitability and plasticity at optimal levels to facilitate the gating, processing and storage of information.

At the circuit level, the basic building blocks of cortical inhibitory microcircuitry are mediated primarily by different subtypes of GABAergic neurons: feedforward inhibition by fast-spiking PV⁺ basket cells, feedback inhibition by burst-spiking SST⁺ Martinotti cells and disinhibition by irregular-spiking VIP⁺ cells that innervate the dendrites of SST⁺ cells⁴⁴. Moreover, late-spiking RELN⁺ cells provide volume inhibition to the distal dendrites of pyramidal neurons³. Although different GABAergic neuronal subtypes target specific cellular compartments, they usually form highly dense synaptic innervation patterns in their projection areas and are largely non-selective for their postsynaptic neuronal partners⁴⁵. Precise stimulation of individual PV⁺ or SST⁺ neurons with two-photon glutamate uncaging and simultaneous recording of postsynaptic inhibitory currents from nearby pyramidal neurons has revealed dense and non-specific functional connectivity of these inhibitory cell types in the cortex^{46,47}. By contrast, activation of VIP⁺ neurons inhibits SST⁺ neurons to “open holes in the blanket of inhibition”⁴⁴. The complex integration of the various GABAergic inhibition units into brain circuitries determines the computation properties of the network.

In addition to preventing runaway excitation, GABAergic inhibition provides precise control over network synchronicity and generates rhythmic oscillations (FIG. 1d). During the prenatal and early postnatal developmental stages in the mammalian brain, GABA is the principal excitatory neurotransmitter that generates oscillatory activity patterns, such as giant depolarizing potentials⁴⁸. Giant depolarizing potentials synchronize activity to instruct the wiring of immature cortical circuits and engage long-term potentiation mechanisms to enhance hippocampal synaptic efficacy⁴⁹. In the adult

brain, hippocampal oscillatory activity patterns, such as gamma oscillations, serve as circuit ‘pacemakers’ to temporally link the activities of widely distributed cells and facilitate information retrieval and consolidation^{50,51}. Spiking of PV⁺ interneurons in the adult mouse brain preferentially correlates with gamma oscillations (30–80 Hz), whereas spiking of SST⁺ interneurons correlates with beta oscillations (15–30 Hz)⁵². At postnatal days 8–10 in rats (the approximate timing of the GABA functional switch in these animals), sustained gamma oscillations emerge in the hippocampus and entrain the activity pattern of the prefrontal cortex⁵³. From these findings taken together, oscillatory network activities sculpted by GABAergic inhibition at different stages of brain development may underlie the refinement and maturation of circuitry and facilitate the proper gating and storage of information⁵⁴.

Homeostatic mechanisms at the synaptic and circuit levels are crucial for fine-tuning the network excitability across space and time. Comparative neuroanatomy studies show that the ratio of excitatory to inhibitory synapses is fairly constant across different brain regions in different species^{55,56}. In response to high neural activity, the strength of GABAergic synapses is homeostatically enhanced by the accumulation of GABA_ARs in the adult mouse brain⁵⁷. Neural activity also regulates the functional development of GABAergic interneurons. Ambient glutamate released during high neural activity preferentially activates NMDA receptor subunit 2C (NR2C)-containing and NR2D-containing NMDA receptors on inhibitory cells⁵⁸. Transient blockade of these receptors during the first week of mouse brain development leads to a long-term reduction in inhibitory synaptic activity and impairs the morphological growth of inhibitory neurons⁵⁸. More than 40% of interneurons die during the first 2 weeks of mouse brain development, apparently owing to intrinsic cell-autonomous mechanisms⁵⁹. However, recent work suggests that interneuron survival in mice during early postnatal development depends on the activity of pyramidal cells, and thus interneuron death is an activity-dependent mechanism to reduce the number of inhibitory cells to achieve homeostasis⁶⁰. Future investigation of the effects of interactions between intrinsic factors and synaptic input on the survival rate of interneurons may reconcile these findings.

Experience-dependent plasticity during early brain development and in adulthood is crucial for animal health and fitness to environmental challenges. Multiple studies indicate a pivotal role of GABA in plasticity during the critical period of development (FIG. 1d). Activity-dependent refinement of functional connections in the developing visual cortex is abolished in *Gad2*-knockout mice, which demonstrate impaired GABA signalling⁶¹. Similarly, blocking GABA_ARs containing the $\alpha 1$ subunit, but not the $\alpha 2$ subunit, impairs critical period plasticity in mice⁶². Brief inhibition of NKCC1 with bumetanide during early development prolongs the plasticity window in the rat visual cortex, indicating the fundamental role of depolarizing GABAergic transmission in defining the window of such plasticity⁶³. In the adult rat brain, activity-dependent reductions

Homeostatic mechanism

Regulatory feedback signals involving changes in synapse number, synaptic strength and GABA signalling efficacy that stabilize neuronal and neural network excitability and function.

Martinotti cells

Small multipolar interneurons, with short branching dendrites, that send projections to layer 1 and provide dendritic inhibition mainly for layer 5 pyramidal neurons to facilitate feedback inhibition.

Critical period

A developmental stage often perturbed in neurodevelopmental disorders, and during which the connectivity of the nervous system is especially susceptible to long-term alterations by environmental stimuli.

Ocular dominance plasticity
Changes in relative responses of visual cortex neurons to stimulation of the two eyes due to visual deprivation. This plasticity is triggered by changes in GABAergic inhibition.

in GABA release at or near active synapses allows the expression of long-term potentiation⁶⁴, and GABAergic control of synaptic plasticity underlies hippocampal memory encoding and retrieval⁶⁵. Remarkably, critical period plasticity can be rapidly induced by enhancing tonic inhibition in the mouse visual cortex⁶⁶, and transplantation of MGE interneuron progenitors into the brains of adult mice reopens the plasticity window⁶⁷. Intriguingly, reduction of GABAergic transmission in the adult rat visual cortex could also partially reactivate ocular dominance plasticity⁶⁸. These results suggest extensive and complex involvement of GABAergic inhibition in determining the onset and closure of developmental critical periods, as well as in adult brain plasticity in the context of learning and memory.

GABAergic dysfunction in NDDs

Driven by the clinical observation that a substantial proportion of individuals with NDDs also have co-morbid seizures, the E/I imbalance hypothesis, first proposed in 2003, states that dysfunctional GABA action in brain circuits is central to NDD pathogenesis⁶⁹. E/I imbalance can arise from perturbations at multiple levels. Within the diverse population of individuals with NDDs, different abnormalities in genetics, molecular activity or neural circuitry may cause cascading alterations that unify in the manifestation of E/I imbalance and NDD symptoms (FIG. 2). In this section, we summarize recent work that comprehensively investigates the E/I imbalance hypothesis as a potentially unifying framework to

understand various subtypes of NDD that may generate mechanistic insight to inform translational studies and advance research for NDD diagnosis and treatment.

Genetic, epigenetic and environmental risk factors. NDDs have strong genetic risk components. Analysis of different cohorts suggests that genetic factors consistently contribute more to the risk of developing ASD than environmental factors do⁷⁰. Cumulatively, results from human genetic studies provide strong support for the E/I imbalance hypothesis of NDDs². Many NDD risk genes encode proteins that are key components of the GABAergic inhibition system, including GABA_AR proteins such as the GABA_AR subunit-β3 (encoded by *GABRB3*)⁷¹ and the presynaptic cell-adhesion molecules neurexin 1 (*NRXN1*)⁷², *NRXN2* (REF.⁷³) and *NRXN3* (REF.⁷⁴). Schizophrenia-associated mutations in the gene encoding the inhibitory synapse-specific postsynaptic cell-adhesion molecule neuroligin 2 cause impairments in NDD-relevant behaviours in mice, including social learning and memory⁷⁵. Copy number variations and exonic deletions in the *GPHN* gene, which encodes the synaptic scaffold protein gephyrin required for GABA_AR clustering and inhibitory synapse formation, have been identified in individuals with ASD, although more recent ASD genetic studies show inconsistencies relating to this association^{76,77}. Loss-of-function mutations in the gene encoding collybistin, a GDP-GTP exchange factor that binds to gephyrin and regulates GABA_AR clustering, may cause severe




Fig. 2 | **Pathogenic mechanisms underlying neurodevelopmental disorders.** A large fraction of neurodevelopmental disorders are caused by genetic mutations and epigenetic aberrances occurring at the whole-organism level or the somatic level that cause deficits in the expression level, localization and interaction pattern of the RNA and protein molecules. Such a plethora of perturbations engages various GABA-related disease mechanisms at the circuit level, leading to the physiological and cognitive impairments present in different subtypes of neurodevelopmental disorders.

X-linked intellectual disability

A subset of male-biased intellectual disability cases that are associated with inheritance of mutant genes on the X chromosome.

Somatic mosaic mutations

Genetic mutations that are absent in the zygote stage but present only in the progeny of mutant cells that occur during the developmental process.

Chromatin looping

Dynamic process in which multiple distal genomic regions are brought into proximity through DNA–protein interactions to provide a structural basis for long-range gene transcription regulation.

encephalopathy involving X-linked intellectual disability and epilepsy⁷⁸. Pathogenic variants of *SLC6A1*, which encodes the voltage-dependent GABA transporter 1 (GAT1) that is primarily expressed in GABAergic neurons and astrocytes, have recently been described in patients with myoclonic atonic epilepsy and intellectual disability⁷⁹. Moreover, rare variations in the regulatory domain of *SLC12A5*, which encodes KCC2, have also been identified in individuals with ASD or schizophrenia⁸⁰.

Many NDD risk genes, including *CHD2* (REF.⁸¹), *FOXP1* (REF.⁸²) and *TCF4* (REF.⁸³), encode transcription factors and chromatin modifiers that may regulate the generation of GABAergic neurons, the formation of inhibitory synapses and the maintenance of E/I balance. Leveraging the human genetic data to identify the molecular pathways in which multiple NDD risk genes converge may shed light on common disease aetiologies.

For example, several ASD risk genes that are associated with high incidences of intellectual disability and seizures, including *MTOR*, *TSC1*, *TSC2*, *PTEN* and *NF1*, are involved in the phosphatidylinositol 3-kinase–mechanistic target of rapamycin (PI3K–mTOR) pathway, which has a central role in integrating metabolic and growth factor signalling pathways to regulate cellular metabolism, growth and survival⁸⁴. Collybistin and gephyrin also bind to mTOR complex 1 and inhibit its signalling, potentially representing a mechanism involving GABAergic synapses and mTOR signalling that contributes to NDD pathogenesis⁸⁵. The WNT signalling pathway represents another ‘hub’ at which multiple NDD risk genes converge. Genes that encode proteins involved in the canonical WNT pathway, including *WNT1*, *WNT2*, *WNT3* and *WNT9B* ligands, and signalling molecules such as adenomatous polyposis coli protein (APC) and β -catenin, and the transcription factor *TCF4*, which mediates the transcriptional output of WNT signalling, have also been implicated in NDD pathogenesis⁸⁶. These results warrant further preclinical studies to investigate the roles of, and the potential for targeting, perturbed signalling pathways in the aetiology of NDDs.

In addition to germline mutations, spontaneous mutations that accumulate during cell division give rise to somatic mosaic mutations that occur at a much higher rate than germline mutations⁸⁷ and that are hard to detect by sequencing blood-derived DNA samples. Depending on the developmental timing of somatic mutation acquisition, mutant cells could be distributed widely in the human brain, presenting a possible mechanism for focal epileptic brain malformations associated with a subset of NDD cases⁸⁸. Somatic mosaic mutations in NDD risk genes such as *CHD2* and *SCN2A* have been identified in blood samples from individuals with ASD⁸⁹. Moreover, somatic copy number variants have been found in NDD risk genes such as *TCF4* and *NRXN1* (REF.⁹⁰). Somatic activation of *AKT3* through copy number variants or activating mutations causes large hemispheric brain malformations⁹¹, indicating that somatic disruption of the PI3K–mTOR pathway may promote growth and survival of mutant cells. Whether somatic mutations affect GABAergic interneurons, and how such

perturbations contribute to NDD pathogenesis, are key questions for future studies.

Epigenetic markers, including DNA methylation and histone modifications, as well as chromatin topological structural features such as chromatin looping, affect the expression of genes involved in cell identity determination, gene expression and responses to physiological stimuli, all of which may be disrupted in NDDs. For example, mutations in *DNMT3A*, which encodes the epigenetic modulator DNA (cytosine 5)-methyltransferase 3A, may disrupt gene methylation patterns, increasing the risk of autism⁹². Knocking out the *Fmr1* gene from neurons in mice results in excessive translation of epigenetic regulators and considerable epigenetic misregulation⁹³. In line with such a mechanism, epigenetic silencing of the expression of the GABA_AR subunit genes *GABRA1* and *GABRB3* (REF.⁹⁴) has been observed in individuals with ASD who do not carry any mutations in these genes. Furthermore, brain tissue samples from individuals with sporadic ASD show reduced expression of glutamic acid decarboxylase 65-kDa protein (GAD65) and GAD67, the rate-limiting enzymes in GABA synthesis⁹⁵.

Notably, epigenetic mechanisms have human-specific features⁹⁶. For example, a CGG trinucleotide repeat expansion mutation at the 5′ untranslated region of the *FMR1* gene, which encodes the synaptic functional regulator FMRP, induces hypermethylation and silencing of this gene. The protein-synthesis function of FMRP can be restored in human induced pluripotent stem cell models of FXS through CRISPR-based targeted demethylation of the CGG repeats⁹⁷. By contrast, insertion of similar-size CGG repeats into the mouse *Fmr1* locus does not result in DNA hypermethylation or repression of *Fmr1* expression, and the resulting gene-edited mice do not show obvious FXS-related phenotypes⁹⁸.

Genes constantly interact with the environment throughout the lifespan. Perinatal exposures to certain environmental risk factors, such as infectious agents, medications, substances of abuse and toxins, may perturb gene-expression profiles to increase the risk of NDDs. During the dynamic and vulnerable fetal stage of human brain development, maternal immune activation (MIA) caused by severe infections during pregnancy is associated with increased frequency of NDDs in children⁹⁹. A mouse model of MIA produces offspring that have an abnormal cortical phenotype as well as impairments in communication and social interaction¹⁰⁰. Optogenetic suppression of pyramidal neuron overexcitation in the primary somatosensory cortex ameliorated the behavioural abnormalities in MIA-affected offspring, suggesting a potential role of GABAergic inhibition in MIA-induced NDD¹⁰¹. Moreover, in two distinct rodent models of environmental factor-induced NDD — prenatal exposure to the antiepileptic drug valproic acid (VPA)^{102–104} and postnatal exposure to the environmental toxin bisphenol A¹⁰⁵ — the expression of KCC2 was considerably reduced. Therefore, understanding the interactions of genetics with epigenetic and environmental factors may help explain the variable severity of disease phenotypes of individuals with shared or related genetic NDD diagnoses.

Convergence of NDD mechanisms. A mechanistic understanding of the shared and distinct pathophysiological pathways in different types of NDD may uncover convergent molecular pathways to be targeted for intervention.

As discussed earlier, there is strong human genetic evidence for the convergence of NDD mechanisms involving perturbations in the mTOR and WNT pathways. Moreover, disruptions in mTOR and WNT signalling have been found in various NDD subtypes. *MECP2*-edited human stem cell-derived neuron models of Rett syndrome show reduced mTOR activity and global reductions in RNA and protein synthesis¹⁰⁶. Furthermore, brain-derived neurotrophic factor (BDNF) and insulin-like growth factor 1 (IGF1), which stimulate the mTOR pathway, ameliorate disease-related phenotypes at the molecular, synaptic and behavioural levels in both male and female mice lacking the X chromosome-linked *Mecp2* (the gene mutated in individuals with Rett syndrome)^{106,107}. Extracellular signal-regulated kinase (ERK) signalling and WNT signalling are also disrupted in a mouse model of Rett syndrome¹⁰⁸. Conditional knockout of the gene encoding β -catenin, a critical component of the canonical WNT pathway, specifically from PV⁺ GABAergic neurons, causes ASD-like behaviour in mice¹⁰⁹, whereas *Apc*-knockout mice show increased β -catenin levels but also show ASD-like behaviours¹¹⁰. In the *Pten*^{+/-} mouse model of ASD, β -catenin expression is elevated and contributes to abnormalities in cell division and brain development¹¹¹. The ASD risk gene *CHD8*, which encodes chromodomain helicase DNA-binding protein 8, regulates WNT signalling in a cell type-dependent manner¹¹². Together, these results indicate that stringent regulation of the mTOR and WNT pathways at optimal levels may be necessary for normal brain function.

The many syndromic forms of NDD have distinct genetic bases but display partially overlapping pathological features, including E/I imbalance. Mouse models of Rett syndrome carrying a mutant allele of *Mecp2* show reduced inhibitory and excitatory conductances in cortical neurons and increased E/I ratio¹¹³, increased occurrence of epilepsy and breathing apnoea¹¹⁴, suggesting disrupted GABAergic inhibition. Down syndrome is caused by trisomy of chromosome 21, and is characterized by intellectual disability and hippocampal dysfunction. In mouse models of Down syndrome, altered GABAergic neurotransmission impairs long-term potentiation^{115–117}, which is rescued both by GABA_AR antagonism and by restoring physiological inhibitory transmission with bumetanide^{117,118}. *Fmr1*-knockout mouse models of FXS exhibit reduced tonic inhibition^{119,120}, network hyperexcitability¹²¹ and abnormal striatal GABA transmission¹²². In mouse models of Angelman syndrome, an NDD whose symptoms include developmental delay, language disorder, movement disorder and seizures, imprinted silencing of *Ube3a* causes hyperexcitability in the brain, partly owing to a disruption in tonic inhibition¹²³. CDKL5 syndrome is a severe NDD caused by mutations in the *CDKL5* gene and involves early-life seizures, autistic behaviours

and intellectual disability. Knocking out *Cdkl5* in mice alters inhibitory transmission in the cerebellum¹²⁴. Moreover, restoring the expression of the GABA synapse regulator neuronal PAS domain-containing protein 4 (NPAS4) in the prefrontal cortex reverses synaptic and behavioural deficits in a 16p11.2-duplication mouse model¹²⁵. Together, these observations suggest convergence of NDD mechanisms on perturbations in GABAergic signalling.

When determining potential target genes for NDD treatment, one should fully consider the ‘survivor’s bias’ in human genetic studies: that is, congenital mutations in genes essential for survival are rarely identified by DNA sequencing in individuals with NDDs. For example, in mice, congenital loss of *Slc12a5*, which encodes KCC2, is incompatible with life¹²⁶. Therefore, protein-disrupting mutations in the coding region of *SLC12A5* are extremely rare in humans, and few regulatory-domain variations of *SLC12A5* have been identified in individuals with ASD or schizophrenia⁸⁰. Nevertheless, mounting evidence demonstrates impaired expression or function of KCC2 in many mouse models of NDD, including those of Rett syndrome³³ or FXS¹²⁷, as well as *Chd8*-mutant mice¹²⁸ and VPA-induced ASD models^{102–104}. In a mouse model of Down syndrome, a substantial increase in NKCC1 expression but no alteration in KCC2 expression was reported¹¹⁷. Similarly, increased NKCC1 expression and reduced KCC2 expression were reported in human tuberous sclerosis complex and focal cortical dysplasia brain specimens¹²⁹. Therefore, various NDD subtypes may share a common mechanism of misregulated KCC2 and/or NKCC1 expression, which may result in excessive intraneuronal chloride levels that cause runaway excitation, seizure activity and overall E/I imbalance in neural circuits.

Clinical research into NDDs further supports the E/I imbalance hypothesis. For example, the correlation between GABA levels and the strength of GABAergic inhibition, as measured by binocular rivalry, a behavioural biomarker that relies on E/I balance, is disrupted in the brains of individuals with ASD¹³⁰. Moreover, the typical correlation between GABA concentrations and gamma-band coherence, another network property reliant on E/I balance, is not observed in individuals with ASD¹³¹. An electroencephalography (EEG)-based study revealed larger functional E/I variability in children with ASD than in typically developing children¹³². A recent study demonstrated altered visual discrimination in patients with FXS that is paralleled by similar changes caused by altered PV⁺ neuron activity in a mouse model of FXS, indicating a potentially translatable biomarker for investigating E/I balance in patients with NDDs¹³³.

A common dysfunction underlying NDD is a reduction in the number of GABAergic interneurons in the brain. In post-mortem brain tissue from individuals with ASD, the number of PV⁺ neurons was decreased and the abundance of PV-encoding mRNA downregulated¹³⁴. A similar phenotype of reduced interneuron cell number has been recapitulated in several mouse models of ASD. A mouse model carrying mutations in the presynaptic neurexin family gene that encodes contactin-associated

Syndromic forms of NDD

A clinical classification of neurodevelopmental disorder (NDD) characterized by patterned neurobehavioural phenotypes and defined genetic causes, including chromosomal aberrations, copy number variations and single gene mutations.

Binocular rivalry

A visual phenomenon regulated by GABAergic inhibition in which different images presented to each eye compete for awareness, resulting in alternating perception.

protein-like 2 (CNTNAP2) exhibits reduced interneuron cell density, as well as epilepsy and ASD-like behaviours in all three core domains relevant to the disorder: stereotypical behaviours, reduced sociability and impaired communication¹³⁵. Mice carrying mutations in NDD risk genes, including those encoding the postsynaptic scaffold proteins SHANK1 and SHANK3 (REF.¹³⁶), the transcription factors MECP2 (REF.¹³⁷) and ARID1B¹³⁸ and the phosphatase PTEN¹³⁹, also exhibit decreased interneuron cell number and/or reduced PV expression. Similar decreases in PV⁺ neuron density were also reported in prenatal VPA-exposed mice, which also show dysfunction in PV⁺ neuron-related neural circuits in the cortex and striatum¹⁴⁰. Interestingly, higher-than-normal numbers of interneurons have been reported in the somatosensory cortex of the Ts65Dn mouse model of Down syndrome¹⁴¹. Another study of post-mortem tissue samples from children with ASD reported cortical disorganization and abnormal expression of glutamatergic neuronal markers, but mild to no changes in the expression of GABAergic markers¹⁴². A systematic analysis of interneuron density in different NDD subtypes may promote the development and application of therapies that normalize interneuron number.

GABA signalling in NDD-related circuit and behaviour abnormalities. Driven by the genetic-level and molecular-level dissection of NDD aetiology, outstanding questions emerge regarding how converging genetic and molecular deficits affect the function of different cell populations, and how neural circuit-level perturbations give rise to behavioural symptoms (FIG. 2). Risk-associated mutations are typically present in many cell types in the brain. It is therefore crucial to generate a systematic understanding of the NDD-related circuit abnormalities and to further dissect the respective roles of different cell types in mediating brain circuit dysfunction.

Dravet syndrome, a form of intractable childhood-onset epilepsy that is associated with sleep disorder, cognitive deficits, autistic-like behaviours, intellectual disability and sometimes sudden unexpected death in epilepsy, provides an example to dissect the pleiotropic roles of disease risk genes in different cell types. Dravet syndrome is caused primarily by heterozygous mutations in the sodium channel gene *SCN1A* or, in some cases, in its paralogue *SCN2A*. *SCN1A* encodes the α -subunit of Na_v1.1, the primary voltage-gated Na⁺ channel in several classes of GABAergic interneurons. Therefore, in *Scn1a*^{-/-} or *Scn1a*^{+/-} mice, the sodium current density is selectively and substantially reduced in inhibitory interneurons but in not excitatory pyramidal neurons¹⁴³. Similarly, specific deletion of *Scn1a* from inhibitory interneurons in mice is sufficient to cause seizures and premature death¹⁴⁴. By contrast, *SCN2A*, which encodes the α -subunit of the Na_v1.2 channel, is expressed mainly in excitatory neurons¹⁴⁵, and Na_v1.2 haploinsufficiency in excitatory neurons is sufficient to trigger epilepsies in mice¹⁴⁶. A shared pathological feature of depolarizing GABA reversal potential was detected in the neocortical and hippocampal pyramidal neurons of

two mouse models of Dravet syndrome: one involving haploinsufficiency of *Scn1a*, and another in which both copies of *Scn1b*, which encodes the β -subunit of Na_v1.1, are deleted¹⁴⁷. Whether the depolarizing effect of GABA is caused by haploinsufficiency of Na_v1.1 or Na_v1.2 in pyramidal neurons, or arises to compensate for the deficits in GABAergic inhibition, remains to be elucidated.

Another example of congenital mutations that cause brain region-specific and cell type-specific abnormalities is the NDD risk gene encoding patched-domain containing protein 1 (PTCHD1), which is implicated in about 1% of individuals with intellectual disability and ASD¹⁴⁸. In mice, *Ptchd1* is selectively expressed in the thalamic reticular nucleus (TRN), which consists mostly of PV⁺ GABAergic neurons and gates the information flow between the cortex and the thalamus¹⁴⁹. *Ptchd1*^{Y/-} mice show attention-deficit hyperactivity disorder-like symptoms and impairments in attention, locomotion and learning¹⁴⁹. GABAergic neurons in the TRN of wild-type mice express very low levels of KCC2 and show depolarizing GABA responses, contributing to the generation of burst firing in the TRN¹⁵⁰; however, such GABA-mediated TRN burst firing is impaired in *Ptchd1*^{Y/-} mice, leading to reductions in sleep spindle activity and highly fragmented sleep¹⁴⁹. Sleep disorder is a common co-morbidity of NDDs, and is present in sporadic ASD¹⁵¹, Rett syndrome¹⁵² and Dravet syndrome¹⁵³. Therapeutic strategies that target striatal GABAergic circuitry might ameliorate sleep disruptions in individuals with NDDs.

A mechanistic understanding of the roles of NDD risk genes in specific cell populations should yield biological insights that facilitate the development of targeted therapy. Modern conditional and intersectional genetic manipulation tools enable targeting of such genes in genetically defined subsets of neurons¹⁵⁴. For example, although MECP2 is expressed throughout the mammalian brain, targeted knockout of *Mecp2* from all GABAergic neurons or a subset of forebrain GABAergic neurons in mice recapitulates many Rett syndrome and autistic features, including repetitive behaviours, motor deficits and breathing apnoea¹⁵⁵. By contrast, restoring *Mecp2* specifically in GABAergic neurons is sufficient to rescue multiple disease features in male *Mecp2*^{Y/-} mice or female *Mecp2*^{X/-} mice¹⁵⁶. Knocking out *Ube3a* from GAD2⁺ cells in mice causes Angelman syndrome-like EEG abnormalities and enhances seizure susceptibility¹⁵⁷, whereas knocking out *Shank3* in a subset of inhibitory neurons causes abnormal social and locomotor behaviours¹⁵⁸. Knocking out the gene encoding the GABA_A δ -subunit specifically from cerebellar granule cells causes anxiety-like and altered social behaviours without affecting motor performance¹⁵⁹, suggesting that disruptions of non-motor functions of the cerebellum that are mediated by tonic GABAergic inhibition may contribute to certain NDD symptoms.

Optogenetics and chemogenetics enable modulation of specific cell population activities to illuminate the roles of neural circuits in behaviour. In support of the E/I imbalance hypothesis of ASD, optogenetic activation of excitatory neurons in the medial prefrontal

cortex induced high-frequency rhythmicity and impaired social behaviour in mice¹⁶⁰. Moreover, optogenetic activation of GABAergic neurons in the medial amygdala enhanced social behaviour, whereas activation of glutamatergic neurons in the same region increased repetitive behaviour¹⁶¹. Furthermore, chemogenetic activation of PV⁺ neurons in a mouse model of FXS reversed impairments in perceptual learning¹³³. Taken together, these preclinical mechanistic studies highlight the contribution of GABAergic neurons to multiple core NDD-related symptoms.

The brain is highly plastic at the synaptic and circuit levels, and constantly undergoes homeostatic adjustments. NDD risk genes play a major part in regulating neural circuit plasticity. Visual cortex plasticity is impaired in mouse models of Rett syndrome¹⁶² and Angelman syndrome¹⁶³, whereas the barrel cortex plasticity window is delayed in a mouse model of FXS¹⁶⁴. Inhibiting NKCC1 during a developmental critical period restores somatosensory cortex synaptic plasticity in FXS-model mice¹⁶⁵, suggesting that disruptions of chloride homeostasis may underlie cortical plasticity impairments in NDDs.

NDD risk genes also modulate homeostasis in the brain. Perturbations that exceed the correcting ability of homeostatic plasticity may lead to NDD symptoms, whereas overcompensation may render homeostatic mechanisms maladaptive and cause secondary disruptions to brain function¹⁶⁶. *Shank3* is crucial for homeostatic compensation in mouse visual cortical circuits to recover from perturbations to sensory drive¹⁶⁷. Similarly, abnormal sensory-evoked responses have been reported in individuals with ASD or FXS¹⁶⁸, and in mouse models of Rett syndrome and tuberous sclerosis complex¹⁶⁹. Surprisingly, a recent study reported that in four mouse models of ASD (*Fmr1*, *Cntnap2* and *Tsc2* mutants and mice with 16p11.2 deletion), the sensory-evoked firing rates of somatosensory cortex neurons are largely normal, despite a shared decrease in inhibitory conductance¹⁷⁰. The authors of the study concluded that the E/I imbalance observed in these mouse models may be a homeostatic response to normalize synaptic drive. Further work that takes into consideration the potential alterations in the polarity of the effects of GABA in these NDD models may shed light on whether homeostatic mechanisms cause or correlate with sensory response abnormalities.

Targeting inhibition to treat NDDs

The prevailing view is that changes to brain function in individuals with NDDs are irreversible. However, landmark studies using mouse models of Rett syndrome show that restoring *Mecp2* in *Mecp2*-null adult mice can reverse most disease-related deficits even after disease onset¹⁷¹. Similarly, phenotypic rescue through gene restoration in adult animals has been achieved in mouse models of NDDs carrying mutations in *Shank3* (REF.¹⁷²) or *Fmr1* (REF.¹⁷³). These results suggest that NDD brains are not 'broken' beyond repair, but perhaps are just 'out of tune', and that appropriate therapeutic interventions could largely reverse symptoms even after disease onset.

DNA- and RNA-targeting therapies. Gene-replacement and gene-editing therapies are promising therapeutic avenues that may correct the genetic root cause of the monogenic subtypes of NDD. Gene-replacement therapy typically uses a viral vector to transfer genes of interest to the target cells to compensate for the faulty endogenous genes (FIG. 3a). In mouse models of Rett syndrome or FXS, viral deliveries of *MECP2* or *FMR1*, respectively, are well tolerated and confer promising phenotypic reversal^{173,174}. Gene-editing therapy that aims to correct disease-causing mutations at their original loci using CRISPR or transcription activator-like effector nucleases (TALENs) (FIG. 3b) has the advantages of maintaining existing spatial and temporal patterns of endogenous gene regulation. Clinical trials of CRISPR-mediated gene-repair therapy targeting the mutant *CEP290* gene have been initiated for the treatment of the retinopathy type 10 Leber congenital amaurosis¹⁷⁵.

For NDDs caused by aberrant gene expression, rather than protein-disrupting mutations, one approach is to repurpose catalytically inactive CRISPR variants as programmable epigenome-editing tools that recruit epigenetic modifiers to the gene of interest and modulate its transcriptional output without changing the DNA sequence^{176,177} (FIG. 3c). Targeted demethylation of the *FMR1* gene in a human embryonic stem cell-derived neuronal model of FXS leads to gene reactivation and functional rescue⁹⁷.

Currently, the application of gene therapies is limited by the inefficiency of viral vectors in targeting the brain, and by the potential for overexpression or underexpression of dose-sensitive target genes. Substantial improvements to viral or non-viral gene delivery systems are needed to deliver the right amount of the gene to the right places at the right time and thus unleash the full potential of gene therapy. Another approach is to use conveniently administrable pharmacological modulation of epigenetic mechanisms to alleviate disease symptoms, as demonstrated by bromodomain-containing protein 4 (BRD4) inhibition in FXS neurons⁹³ and histone deacetylase (HDAC) inhibition in SHANK3-deficient mice¹⁷⁸.

RNA molecules can be encapsulated in lipid nanoparticles and delivered into cells with relative ease compared with DNA molecules. Delivery of mRNA transiently increases target protein translation¹⁷⁹ (FIG. 3d), whereas delivery of RNA interference (RNAi) therapeutics temporarily degrades specific RNA transcripts, silencing gene expression¹⁸⁰. Moreover, antisense oligonucleotides, short modified DNA sequences that hybridize and silence target mRNA transcripts, have remarkable in vivo stability (FIG. 3e). Brain delivery of antisense oligonucleotides to knock down *MECP2* transcripts reversed disease phenotypes in a mouse model of *MECP2*-duplication syndrome¹⁸¹. Remarkably, a customized antisense oligonucleotide treatment of one individual with Batten disease, a disorder caused by misspliced RNA transcripts, demonstrated good safety and efficacy that ameliorated behavioural symptoms and reduced epileptic seizures¹⁸². These promising, life-changing results highlight a novel avenue of developing precision molecular medicine for NDDs.

Transcription activator-like effector nucleases (TALENs). Artificial DNases engineered through fusing a transcription activator-like effector DNA-binding domain to a DNA cleavage domain for the purpose of cutting and editing specific DNA sequences.




Fig. 3 | Therapeutic opportunities at the genetic level for managing NDDs. **a** | Gene replacement therapies use a virus to introduce a functional transgene copy of the mutant neurodevelopmental disorder (NDD) risk gene to restore mRNA and protein production. **b** | By contrast, gene-editing therapies use technologies such as CRISPR–Cas9 to correct mutant genes at their endogenous loci. **c** | Catalytically inactive Cas9 can be repurposed to modify the epigenetic status of specific genes to activate or silence their expression without changing the primary DNA sequence. **d** | RNA-based therapies modulate gene expression levels in target cells by delivering mRNA, which can be further translated into protein products. **e** | Other RNA therapies modulate gene expression levels by delivering RNA interference (RNAi)-based therapeutics or antisense oligonucleotides (ASOs) to knock down particular RNA transcripts.

Protein-targeting therapies. For NDD subtypes of polygenic or sporadic origin, therapies designed to target a particular gene are not a treatment option. A strategy to overcome this limitation is to develop drugs that bypass the upstream genetic or environmental causes, to directly target the proteins that perform much cellular signalling and function. Uncovering common NDD disease mechanisms and developing therapies that rectify common perturbations in protein expression or function may result in symptomatic relief for NDDs, regardless of how complex or uncertain the cause may be, analogous to how a pair of glasses can provide symptomatic relief to individuals with myopia, regardless of the root causes.

Most small-molecule drugs, including variants of benzodiazepine that are positive allosteric modulators of GABA_ARs¹⁸³ and variants of baclofen that are GABA_BR agonists, bind to target proteins to change their structure and function (FIG. 4a). (*R*)-Baclofen treatment effectively reversed synaptic, cognitive and social deficits in mouse models of FXS¹⁸⁴ and 16p11.2-deletion syndrome¹⁸⁵. However, clinical trials of (*R*)-baclofen in patients with FXS were unable to demonstrate any improvement in behaviour end points, potentially owing to the advanced age of the participants and the limited duration of treatment¹⁸⁶. Drugs that reduce NKCC1 activity or increase KCC2 activity should enhance the efficacy of GABAergic inhibition and may confer benefits to patients with NDDs, and bumetanide and VU0463271 have been identified as specific blockers of NKCC1 (REF.¹⁸⁷) and KCC2 (REF.¹⁸⁸), respectively. A newly

developed compound, ARN23746, shows selective inhibition of NKCC1 versus NKCC2 and KCC2 (REF.¹⁰⁴). However, so far no drug has been discovered that can facilitate the complex transporter function of KCC2. CLP257, a recently identified compound that enhances KCC2 membrane trafficking, alleviates hypersensitivity in a rat model of neuropathic pain¹⁸⁹, although controversy has arisen over the mechanism of action of this compound^{190,191}. An alternative approach to modulate the activities of KCC2 and NKCC1 is through altering their post-translational modifications; for example, by targeting with-no-lysine kinase (WNK), which phosphorylates KCC2 and NKCC1 to inhibit or activate their function, respectively^{192,193}. A knock-in mouse model expressing a dephosphomimetic version of KCC2 (KCC2-T906A/T1007A) shows reduced susceptibility to chemoconvulsant-induced epileptiform activity¹⁹⁴. Whether WNK inhibitors are safe and efficacious in promoting KCC2 activity and treating NDDs is a topic of considerable interest for both basic research and clinical investigations.

Pharmacological modulation of common molecular pathways perturbed in many NDD subtypes, such as the mTOR and WNT pathways, could confer broadly applicable therapeutic benefits (FIG. 4b). IGF1, which stimulates the AKT–mTOR pathway, shows promising results in preclinical models of Rett syndrome, and treatment with new specific inhibitors of glycogen synthase kinase- α (GSK3 α), a key WNT pathway component, corrects pathophysiological abnormalities in a mouse




Fig. 4 | Therapeutic opportunities at the molecular level for managing NDDs. Various drugs have been developed to modulate the molecular processes in cells through binding to the target proteins to alter their biological activities (part **a**), modulating the activities of molecular signalling pathways (part **b**), altering the interactions between the target proteins and other proteins (part **c**) or facilitating the degradation of target proteins (part **d**). Moreover, novel therapeutics have been developed to modulate the expression levels of the genes that encode the target proteins (part **e**).

model of FXS¹⁹⁵. However, a randomized clinical trial that treated girls with Rett syndrome with recombinant human IGF1 (also called mecasermin) did not reveal statistically significant alleviation of clinical symptoms¹⁹⁶. Nevertheless, a tripeptide segment of IGF1, which is effective in a mouse model of Rett syndrome¹⁶², has exhibited efficacy (via the compound trofinetide) in phase I and phase II trials in Rett syndrome, and is now in phase III trials^{197,198}. These results highlight the importance of further investigating the pharmacokinetics and bioavailability of pathway-modulating drugs to facilitate clinical translation.

Complex protein–protein interactions are crucial in cellular processes such as gene transcription, intracellular signalling and synapse formation. Characterization of the ‘interactome’ of proteins that bind strongly to NDD-relevant proteins such as KCC2 may identify protein–interaction partners that may be targeted therapeutically⁴³. Moreover, weak interactions between the intrinsic disordered regions of member proteins mediate dynamic partitioning of phase-separated protein condensates in cells^{199,200}. NDD-relevant proteins such as MECP2 and FMRP form intracellular condensates that may contribute to their functions²⁰¹. Protein condensates localized at glutamatergic and GABAergic synapses show high affinity and selectivity for their respective component proteins²⁰². Drugs that either preferentially undergo partitioning into or mediate the assembly or dissipation of target protein condensates specifically in GABAergic neurons or GABAergic synapses may exhibit increased therapeutic efficacy and reduced off-target effects (FIG. 4c).

The ASD risk genes *UBE3A* and *CUL3* are involved in protein degradation via ubiquitin ligase and proteasomes²⁰³, suggesting that disrupted protein homeostasis

may contribute to NDD pathogenesis. An emerging drug development approach, proteolysis-targeting chimeras (PROTACs), uses small-molecule compounds to recruit endogenous destruction complex machinery to degrade target proteins, potentially compensating for impaired proteostasis in certain NDDs²⁰⁴ (FIG. 4d).

By leveraging human stem cell and genome-editing technologies, sophisticated cell-based disease models and high-throughput screening assays can be developed to investigate human genes and protein networks in their native cellular contexts, opening up possibilities to screen small-molecule chemicals or nucleic acid libraries for potential therapeutics to modulate the transcriptional and translational regulatory programmes of target genes (FIG. 4e). For example, *SLC12A5*, which encodes KCC2, is an appealing therapeutic target gene that is silenced in multiple subtypes of NDD. Although KCC2 is selectively expressed in neurons, previous KCC2 drug-screening efforts relying on non-neuronal cell lines failed to identify compounds that increase KCC2 levels, possibly because these cells lack the cellular and genomic context that enables KCC2 expression²⁰⁵. To overcome this hurdle, a recent study used CRISPR to insert a luciferase reporter gene into the *SLC12A5* locus to create a convenient readout of the *SLC12A5* gene expression level in human neurons. Unbiased screening of the effects of a library including many existing safety-approved compounds on such reporter neurons enabled the discovery of the first group of KCC2 expression-enhancing compounds (KEECs) and revealed previously uncharacterized molecular pathways that regulate *SLC12A5* expression in neurons²⁰⁶. Repurposing already approved drugs or drug-like molecules for the treatment of NDDs facilitates the translation from bench to bedside.

Proteolysis-targeting chimeras

(PROTACs) Engineered small molecules composed of two distinct domain classes: one that engages E3 ubiquitin ligase and the other that binds to target proteins for degradation.




Fig. 5 | Therapeutic opportunities at the circuit level for managing NDDs. At the circuit level, drugs have been developed to regulate the excitability of neurons through modulating the activity or expression of ion channels and receptors (part a). Neuronal chloride transporters are master regulators of the polarity and efficacy of GABAergic signalling, and therefore are a good target for therapeutic development (part b). Experimental therapeutic modalities are also under development to engage endogenous neuromodulatory mechanisms, such as engaging oxytocin signalling (part c), direct modulation of the activity of target neuronal populations with optogenetics or chemogenetics (part d) or restoration of the density of inhibitory neurons through transplantation of in vitro-differentiated GABAergic interneurons (part e). GABA_AR, GABA type A receptor; PS cell, pluripotent stem cell; PVN paraventricular nucleus.

Neural circuit-targeting therapies. At the neural network level, drugs that alter the functional activity or expression level of target proteins exert cascading effects on both the cells expressing the target proteins and other connected cell populations. Studies in the *Scn1a*^{+/-} mouse model of Dravet syndrome²⁰⁷ and the BTBR mouse model of idiopathic ASD²⁰⁸ have demonstrated that low doses of benzodiazepine variants such as clonazepam and L-838417 can normalize social and cognitive behaviours in these animals, potentially through potentiating GABAergic inhibition (FIG. 5a). However, pharmacological potentiation of GABA signalling in the neonatal rat brain exacerbates seizures, owing to

NKCC1-mediated chloride accumulation³⁵. Treatment of mouse models of FXS^{103,165} or Down syndrome¹¹⁷ or mice with a VPA-induced ASD-like phenotype¹⁰³ with the NKCC1 blocker bumetanide ameliorated electrophysiological and behavioural phenotypes. In clinical trials, off-label use of bumetanide conferred symptomatic benefits for both individuals with sporadic ASD and individuals with FXS^{209,210}, although a recent study showed efficacy of bumetanide in reducing repetitive behaviour in only a small subset of patients with ASD²¹¹. These findings support the notion that pharmacologically restoring chloride homeostasis can provide symptomatic relief for various NDDs (FIG. 5b).

However, bumetanide triggers increased diuresis and electrolyte imbalance in adult patients, mainly owing to non-specific inhibition of NKCC2 in the kidney²¹². A recently developed NKCC1-selective inhibitor may reduce such safety concerns and enable long-term clinical application of chloride-normalizing drugs¹⁰⁴.

Unlike NKCC1 and NKCC2, KCC2 has a brain-specific and neuron-restricted expression pattern²¹³. Thus, targeting KCC2 has reduced risk of off-target effects throughout the body. A recently identified group of small-molecule KEECs rescued electrophysiological and behavioural phenotypes in human embryonic stem cell-derived neuron and mouse models of Rett syndrome²⁰⁶. Treatment of wild-type neurons with a KEEC substantially increased KCC2 expression but did not change neuronal morphology or function, which is relevant for Rett syndrome and other X-linked NDDs in which both wild-type and mutant cells are present owing to random X-chromosome inactivation. Moreover, viral overexpression of a rat *Slc12a5* transgene in a mouse model of spinal cord injury showed beneficial effects on functional recovery²¹⁴. Together, these results suggest that enhancing KCC2 expression could be a safe approach for NDD treatment.

Engaging endogenous neuromodulatory signalling mechanisms is a potentially efficacious therapeutic avenue to treat NDDs. Oxytocin is a neuromodulator that is highly relevant to NDD: social deficits caused by reduced oxytocin signalling²¹⁵ are largely mediated by downregulation of KCC2 expression and activity^{103,216}. Several reports suggest that oxytocin released during

child delivery protects fetal neurons from hypoxia and reduces the risk of NDDs by inducing a temporary upregulation of KCC2 (REFS^{103,217}). Intranasal delivery of oxytocin shows promising results in treating small groups of individuals with ASD^{218,219}, but the short half-life of exogenously applied oxytocin limits its effectiveness. An alternative approach is to drive endogenous oxytocinergic signalling in the brain to rescue NDD phenotypes. Indeed, a proof-of-concept study shows that optogenetic stimulation of the oxytocinergic neurons in the paraventricular nucleus of the hypothalamus improves social behaviour in mouse models of ASD²²⁰. Another recent study shows that treatment of various mouse models of NDD with the probiotic bacterial species *Lactobacillus reuteri* alters gut microbiota composition, thereby stimulating vagus nerve afferents innervating the paraventricular nucleus, releasing oxytocin and ameliorating ASD phenotypes^{221,222} (FIG. 5c).

Optogenetics and chemogenetics are novel groups of experimental therapeutic approaches to directly modulate neural circuit activities (FIG. 5d). Optogenetic activation of GABAergic neurons in the medial amygdala increases social behaviour in mice, whereas activation of glutamatergic neurons in the same brain region increases repetitive behaviour¹⁶¹. To obviate the need to implant an optical fibre into the brain and facilitate the application of optogenetics technology for future clinical trials, an ultrasensitive step-function opsin that can be turned on and off via transcranial optical stimulation was recently developed²²³. Moreover, chemogenetic activation of PV⁺ interneurons in the visual cortex




Fig. 6 | Therapeutic and diagnostic opportunities at the individual level for neurodevelopmental disorders. Symptomatic diagnosis of disease-related phenotypes (part a), combined with clinically relevant biomarkers such as electroencephalography, functional MRI, blood and cerebrospinal fluid biomarkers (part b), assists the diagnosis and stratification of patients to receive precision medicine treatment (part c). Moreover, various brain-stimulation methods, including deep brain stimulation (DBS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) (part d) as well as behavioural therapies (part e), may also systematically ameliorate symptoms of neurodevelopmental disorders.

Box 1 | Questions for future research

Here we outline some of the main outstanding questions in the neurodevelopmental disorders (NDDs) research field, and discuss potential approaches to tackle these questions in order to illuminate the causes of NDDs and guide the development of effective treatments.

Biological information flows from the genome and epigenome to RNA and protein molecules in various cell types. How does such information assimilate into large-scale emergent properties that determine neural circuit activities and animal behaviour? Studies that systematically investigate the causal links between molecular information, circuit function and animal behaviour may establish a framework to interpret how biological information is transmitted between these levels.

NDDs often manifest deficits at the molecular, circuit and behaviour levels. How do disease-relevant perturbations cascade through the flow of biological information and lead to NDD symptoms? Investigating how NDD-causing genetic and molecular perturbations cause disease-relevant circuit and behavioural abnormalities may provide opportunities to understand the function and dysfunction of the brain.

Certain aspects of the primate brain and the human brain are fundamentally different from their rodent counterparts. How do primate-specific and human-specific features of GABAergic inhibition contribute to circuit function and NDD-related dysfunction? A systematic comparison of the brains of different species at the levels of single-cell gene expression and large-scale connectivity may lead us closer to the answers.

NDD pathogenesis has a strong male sex bias. Do potential sex-specific features in the development and function of the GABAergic inhibition system contribute to such bias? Investigating the effect of both intrinsic genetic factors and extrinsic hormonal cues on the GABAergic signalling system may yield mechanistic insights.

Glial cells regulate many aspects of neuronal function and connectivity. Do interactions between GABAergic neurons and glial cells contribute to NDD pathogenesis? Cell type-specific perturbations and a systematic analysis may reveal the crosstalk between them.

It has been demonstrated that symptoms of some preclinical models of NDDs can be reversed by replacing disease-causing genes. To what extent could restoring GABAergic inhibition deficits reverse NDD disease symptoms after their onset? Pharmacological modulation of GABAergic signalling may provide broadly applicable therapeutics to ameliorate NDDs.

was sufficient to rescue deficits in sensory processing in *Fmr1*^{-/-} mice¹³³, while activation of glutamatergic neurons in the prefrontal cortex ameliorated cognitive and social impairments in both *16p11*^{+/-} mice and *Shank3*-deficient mice^{224,225}. These brain-stimulating approaches empower mechanistic investigation of the role of GABAergic neurons in NDD pathogenesis and provide promising avenues to develop potential therapies for NDDs that modulate neural circuit activities.

To mitigate the loss of GABAergic neurons in NDD subtypes associated with mutations in genes such as *CNTNAP2*, *ARID1B*, *MECP2* or *PTEN*, a cell therapy approach involves transplanting inhibitory neurons generated in vitro into the brain (FIG. 5e). Mouse MGE-lineage interneurons transplanted into the mouse brain can integrate into the circuit for a long time after transplantation²²⁶, reopen the plasticity window of the host brain⁶⁷ and, in a pilocarpine-treated mouse model of epilepsy, reduce seizure severity²²⁷. Furthermore, GABAergic neurons to be transplanted can be genetically modified to express transgenes that enhance their inhibitory function²²⁸ or to express optogenetic and chemogenetic responsive elements that enable on-demand GABAergic inhibition in the brain. To translate these encouraging approaches for testing into clinical trials, a robust pipeline to produce clinical-grade human cells that closely resemble MGE-derived interneuron progenitor cells would need to be developed, and the

interneuron transplantation procedure would need to be optimized.

Individual-level diagnosis and therapies. A comprehensive framework to understand NDD pathogenesis requires consideration of both genetic and environmental perturbations that cause molecular abnormalities in cells. Such deficits further propagate to affect circuit function, ultimately leading to behavioural symptoms. Following the same logic, therapeutic intervention at the genetic, molecular or circuit level may propagate to positively influence behaviour. Thus, it is crucial to evaluate the progression of NDDs and assess the therapeutic efficacy of interventions at the organism level.

The ability to make early and accurate clinical assessments is the foundation for effective management and treatment of NDDs. Key behavioural metrics such as motor coordination, stereotypical behaviour, eye contact and sleep patterns can be used for diagnosing NDDs and assessing NDD severity (FIG. 6a). A panel of objective biomarkers, such as EEG, MRI, functional MRI, magnetic resonance spectroscopy and whole-genome or whole-exome sequencing biomarkers, as well as body fluid cytokine, antibody and metabolite biomarkers, can be used in conjunction with behavioural assays to assist diagnosis and assessment of disease severity (FIG. 6b). One study used the Autism Diagnostic Observation Schedule and other behavioural assays, together with magnetic resonance spectroscopy measurement of brain GABA concentrations, to reveal that the typical link between GABA levels and the efficacy of inhibition is specifically absent from individuals with ASD¹³⁰. Impairments in gamma frequency oscillations²²⁹ and the disrupted coherence of auditory-evoked gamma-band responses¹³¹ are other neurophysiological biomarkers found in people with ASD and that rely on differences in GABA signalling. Stratification of individuals with NDDs, based on symptomatic diagnosis and various biomarker metrics, could drive evidence-based precision medicine and provide objective measurements with which to assess treatment outcomes (FIG. 6c).

Deep brain stimulation (DBS) has been applied clinically to treat various brain disorders (FIG. 6d). A study reported that DBS applied at 100 Hz to the internal segment of the globus pallidus inhibits local neuronal firing in a GABA_AR-dependent manner in monkeys²³⁰, indicating a potential role of GABA signalling in mediating the beneficial effect of DBS, although the exact cellular and synaptic mechanisms remain unclear. One study demonstrated successful rescue of hippocampal memory with fornical DBS in a mouse model of Rett syndrome²³¹, suggesting potential application of DBS in the treatment of NDDs. Similarly, it may also be worth testing other non-invasive brain stimulation methods, including transcranial magnetic stimulation and transcranial direct current stimulation, in treating NDDs. Cognitive and behavioural therapy tailored to the needs of patients is already commonly used in the clinic to manage NDD symptoms (FIG. 6e). Multimodal treatment approaches that combine medication with organism-level treatment may generate synergistic effects to manage and ameliorate symptoms in individuals with NDDs.

Autism Diagnostic Observation Schedule

A standardized assessment tool that clinicians may use for diagnosing autism spectrum disorder in patients through the use of semistructured play or interview sessions.

Conclusion and perspectives

GABA plays pivotal roles in brain development, physiology and pathophysiology. In this Review, we have discussed GABAergic function and dysfunction in a practical framework comprising the genetic, molecular, circuit and behaviour levels. Gene activities determine the molecular make-up of cells, which assemble into neural circuits that give rise to behavioural phenotypes. Perturbations of this intricate system, such as genetic mutations or aberrant cellular responses to GABA, may propagate throughout the cascade, triggering abnormalities in neural circuit function and causing behavioural symptoms. We have reviewed findings from basic and translational research that support the pivotal role of GABAergic inhibition in pathogenic mechanisms that converge across NDDs, prompting the extension of the E/I imbalance theory

of NDD to include the dynamic changes in neuronal chloride homeostasis. We have also highlighted various treatment modalities that could potentially target GABA signalling in NDDs, including small-molecule drugs, gene and cell therapies, and brain stimulation.

Looking ahead, technological innovations and joint efforts of the global scientific community may help to illuminate a number of fundamental questions regarding the causes of and treatments for NDDs that remain largely unanswered (BOX 1). Approaching these fundamental questions from the angles of basic, translational and clinical research will help deepen our understanding of the marvellous complexity of the brain and provide much-needed treatments for people with NDDs.

Published online 26 March 2021

1. Boyle, C. A. et al. Trends in the prevalence of developmental disabilities in US children, 1997–2008. *Pediatrics* **127**, 1034–1042 (2011).
2. Satterstrom, F. K. et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. *Cell* **180**, 568–584 e523 (2020).
3. Wamsley, B. & Fishell, G. Genetic and activity-dependent mechanisms underlying interneuron diversity. *Nat. Rev. Neurosci.* **18**, 299–309 (2017).
4. Marin, O. Interneuron dysfunction in psychiatric disorders. *Nat. Rev. Neurosci.* **13**, 107–120 (2012).
5. Tasic, B. et al. Shared and distinct transcriptomic cell types across neocortical areas. *Nature* **563**, 72–78 (2018).
6. Nicholas, C. R. et al. Functional maturation of hPSC-derived forebrain interneurons requires an extended timeline and mimics human neural development. *Cell Stem Cell* **12**, 573–586 (2013).
7. Yang, N. et al. Generation of pure GABAergic neurons by transcription factor programming. *Nat. Methods* **14**, 621–628 (2017).
8. Lim, L., Mi, D., Llorca, A. & Marin, O. Development and functional diversification of cortical interneurons. *Neuron* **100**, 294–313 (2018).
9. Marin, O. & Rubenstein, J. L. A long, remarkable journey: tangential migration in the telencephalon. *Rev. Neurosci.* **2**, 780–790 (2001).
10. Bortone, D. & Polleux, F. KCC2 expression promotes the termination of cortical interneuron migration in a voltage-sensitive calcium-dependent manner. *Neuron* **62**, 53–71 (2009).
11. De Marco Garcia, N. V., Karayannis, T. & Fishell, G. Neuronal activity is required for the development of specific cortical interneuron subtypes. *Nature* **472**, 351–355 (2011).
This article reveals the connection between neuronal activity and cortical cellular architecture — specifically, the integration of GABAergic inhibitory neurons into brain circuits.
12. Francavilla, R. et al. Alterations in intrinsic and synaptic properties of hippocampal CA1 VIP interneurons during aging. *Front. Cell Neurosci.* **14**, 554405 (2020).
13. Bartolini, G., Ciceri, G. & Marin, O. Integration of GABAergic interneurons into cortical cell assemblies: lessons from embryos and adults. *Neuron* **79**, 849–864 (2013).
14. Pfeffer, C. K., Xue, M., He, M., Huang, Z. J. & Scanziani, M. Inhibition of inhibition in visual cortex: the logic of connections between molecularly distinct interneurons. *Nat. Neurosci.* **16**, 1068–1076 (2013).
This article describes a number of distinct connectivity patterns between three major cortical inhibitory neuron subtypes, which has implications for understanding the connectivity and computational logic of cortical circuits.
15. Zhang, C. et al. Neurexins physically and functionally interact with GABA_A receptors. *Neuron* **66**, 403–416 (2010).
16. Dong, N., Qi, J. & Chen, G. Molecular reconstitution of functional GABAergic synapses with expression of neuroligin-2 and GABA_A receptors. *Mol. Cell Neurosci.* **35**, 14–23 (2007).
17. Craig, A. M., Banker, G., Chang, W., McGrath, M. E. & Serpinikaya, A. S. Clustering of gephyrin at GABAergic but not glutamatergic synapses in cultured rat hippocampal neurons. *J. Neurosci.* **16**, 3166–3177 (1996).
18. Papadopoulos, T. & Soykan, T. The role of collybin in gephyrin clustering at inhibitory synapses: facts and open questions. *Front. Cell Neurosci.* **5**, 11 (2011).
19. Lee, V. & Maguire, J. The impact of tonic GABA_A receptor-mediated inhibition on neuronal excitability varies across brain region and cell type. *Front. Neural Circuits* **8**, 3 (2014).
20. Caraiscos, V. B. et al. Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by $\alpha 5$ subunit-containing γ -aminobutyric acid type A receptors. *Proc. Natl Acad. Sci. USA* **101**, 3662–3667 (2004).
21. Wei, W., Zhang, N., Peng, Z., Houser, C. R. & Mody, I. Perisynaptic localization of δ subunit-containing GABA_A receptors and their activation by GABA spillover in the mouse dentate gyrus. *J. Neurosci.* **23**, 10650–10661 (2003).
22. Datta, D., Arion, D. & Lewis, D. A. Developmental expression patterns of GABA_A receptor subunits in layer 3 and 5 pyramidal cells of monkey prefrontal cortex. *Cereb. Cortex* **25**, 2295–2305 (2015).
23. Scimemi, A. Structure, function, and plasticity of GABA transporters. *Front. Cell Neurosci.* **8**, 161 (2014).
24. Lee, S. et al. Channel-mediated tonic GABA release from glia. *Science* **330**, 790–796 (2010).
25. Pavlov, I., Savchenko, L. P., Kullmann, D. M., Semyanov, A. & Walker, M. C. Outwardly rectifying tonically active GABA_A receptors in pyramidal cells modulate neuronal offset, not gain. *J. Neurosci.* **29**, 15341–15350 (2009).
26. Chalifoux, J. R. & Carter, A. G. GABA_B receptor modulation of synaptic function. *Curr. Opin. Neurobiol.* **21**, 339–344 (2011).
27. Ben-Ari, Y., Khalilov, I., Kahle, K. T. & Cherubini, E. The GABA excitatory/inhibitory shift in brain maturation and neurological disorders. *Neuroscientist* **18**, 467–486 (2012).
28. Chen, G., Trombley, P. Q. & van den Pol, A. N. Excitatory actions of GABA in developing rat hypothalamic neurons. *J. Physiol.* **494**, 451–464 (1996).
29. Paulus, W. & Rothwell, J. C. Membrane resistance and shunting inhibition: where biophysics meets state-dependent human neurophysiology. *J. Physiol.* **594**, 2719–2728 (2016).
30. Rivera, C. et al. The K⁺/Cl⁻ co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. *Nature* **397**, 251–255 (1999).
This is the first article to demonstrate that KCC2 is the main chloride extruder that mediates the hyperpolarizing GABAergic synaptic transmission in functionally mature neurons.
31. Bao, H. et al. Long-range GABAergic inputs regulate neural stem cell quiescence and control adult hippocampal neurogenesis. *Cell Stem Cell* **21**, 604–617 e605 (2017).
32. Banke, T. G. & McBain, C. J. GABAergic input onto CA3 hippocampal interneurons remains shunting throughout development. *J. Neurosci.* **26**, 11720–11725 (2006).
33. Tang, X. et al. KCC2 rescues functional deficits in human neurons derived from patients with Rett syndrome. *Proc. Natl Acad. Sci. USA* **113**, 751–756 (2016).
This work uncovers a link between reduction in KCC2 expression and the impaired GABA functional switch in a human induced pluripotent stem cell-derived neuronal model of Rett syndrome, indicating a pathological mechanism underlying neural circuit function abnormalities observed in patients.
34. Vanhatalo, S. et al. Slow endogenous activity transients and developmental expression of K⁺-Cl⁻ cotransporter 2 in the immature human cortex. *Eur. J. Neurosci.* **22**, 2799–2804 (2005).
35. Dzhala, V. I. et al. NKCC1 transporter facilitates seizures in the developing brain. *Nat. Med.* **11**, 1205–1213 (2005).
36. Wang, D. D. & Kriegstein, A. R. GABA regulates excitatory synapse formation in the neocortex via NMDA receptor activation. *J. Neurosci.* **28**, 5547–5558 (2008).
37. Nakanishi, K., Yamada, J., Takayama, C., Oohira, A. & Fukuda, A. NKCC1 activity modulates formation of functional inhibitory synapses in cultured neocortical neurons. *Synapse* **61**, 138–149 (2007).
38. Pfeffer, C. K. et al. NKCC1-dependent GABAergic excitation drives synaptic network maturation during early hippocampal development. *J. Neurosci.* **29**, 3419–3430 (2009).
39. Li, H. et al. KCC2 interacts with the dendritic cytoskeleton to promote spine development. *Neuron* **56**, 1019–1033 (2007).
40. Gauvain, G. et al. The neuronal K-Cl cotransporter KCC2 influences postsynaptic AMPA receptor content and lateral diffusion in dendritic spines. *Proc. Natl Acad. Sci. USA* **108**, 15474–15479 (2011).
41. Chevy, Q. et al. KCC2 gates activity-driven AMPA receptor traffic through cofilin phosphorylation. *J. Neurosci.* **35**, 15772–15786 (2015).
42. Llano, O. et al. KCC2 regulates actin dynamics in dendritic spines via interaction with β -PIX. *J. Cell Biol.* **209**, 671–686 (2015).
43. Mahadevan, V. et al. Native KCC2 interactome reveals PACSIN1 as a critical regulator of synaptic inhibition. *eLife* **6**, e28270 (2017).
44. Karnani, M. M. et al. Opening holes in the blanket of inhibition: localized lateral disinhibition by VIP interneurons. *J. Neurosci.* **36**, 3471–3480 (2016).
45. Karnani, M. M., Agetsuma, M. & Yuste, R. A blanket of inhibition: functional inferences from dense inhibitory connectivity. *Curr. Opin. Neurobiol.* **26**, 96–102 (2014).
46. Fino, E. & Yuste, R. Dense inhibitory connectivity in neocortex. *Neuron* **69**, 1188–1203 (2011).
47. Packer, A. M. & Yuste, R. Dense, unspecific connectivity of neocortical parvalbumin-positive interneurons: a canonical microcircuit for inhibition? *J. Neurosci.* **31**, 13260–13271 (2011).
48. Ben-Ari, Y., Gaiarsa, J. L., Tyzio, R. & Khazipov, R. GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations. *Physiol. Rev.* **87**, 1215–1284 (2007).
49. Kasyanov, A. M., Safulina, V. F., Voronin, L. L. & Cherubini, E. GABA-mediated giant depolarizing potentials as coincidence detectors for enhancing synaptic efficacy in the developing hippocampus. *Proc. Natl Acad. Sci. USA* **101**, 3967–3972 (2004).

50. Buzsáki, G. & Draguhn, A. Neuronal oscillations in cortical networks. *Science* **304**, 1926–1929 (2004).
51. Colgin, L. L. & Moser, E. I. Gamma oscillations in the hippocampus. *Physiology* **25**, 319–329 (2010).
52. Chen, G. et al. Distinct inhibitory circuits orchestrate cortical beta and gamma band oscillations. *Neuron* **96**, 1403–1418 e1406 (2017).
53. Brockmann, M. D., Poschel, B., Cichon, N. & Hanganu-Opatz, I. L. Coupled oscillations mediate directed interactions between prefrontal cortex and hippocampus of the neonatal rat. *Neuron* **71**, 332–347 (2011).
54. Le Magueresse, C. & Monyer, H. GABAergic interneurons shape the functional maturation of the cortex. *Neuron* **77**, 388–405 (2013).
55. Hsu, A., Luebke, J. I. & Medalla, M. Comparative ultrastructural features of excitatory synapses in the visual and frontal cortices of the adult mouse and monkey. *J. Comp. Neurol.* **525**, 2175–2191 (2017).
56. Cline, H. Synaptogenesis: a balancing act between excitation and inhibition. *Curr. Biol.* **15**, R203–R205 (2005).
57. Rannals, M. D. & Kapur, J. Homeostatic strengthening of inhibitory synapses is mediated by the accumulation of GABA_A receptors. *J. Neurosci.* **31**, 17701–17712 (2011).
58. Hanson, E. et al. Tonic activation of GluN2C/GluN2D-containing NMDA receptors by ambient glutamate facilitates cortical interneuron maturation. *J. Neurosci.* **39**, 3611–3626 (2019).
59. Southwell, D. G. et al. Intrinsically determined cell death of developing cortical interneurons. *Nature* **491**, 109–113 (2012).
60. Wong, F. K. et al. Pyramidal cell regulation of interneuron survival sculpts cortical networks. *Nature* **557**, 668–673 (2018).
61. Hensch, T. K. et al. Local GABA circuit control of experience-dependent plasticity in developing visual cortex. *Science* **282**, 1504–1508 (1998).
This is the first article to demonstrate the role of GABAergic inhibitory transmission in regulating the strength of experience-dependent plasticity and the developmental critical period window in the cortex.
62. Fagiolini, M. et al. Specific GABA_A circuits for visual cortical plasticity. *Science* **303**, 1681–1683 (2004).
63. Deidda, G. et al. Early depolarizing GABA controls critical-period plasticity in the rat visual cortex. *Nat. Neurosci.* **18**, 87–96 (2015).
64. Davies, C. H., Starkey, S. J., Pozza, M. F. & Collingridge, G. L. GABA autoreceptors regulate the induction of LTP. *Nature* **349**, 609–611 (1991).
65. Paulsen, O. & Moser, E. I. A model of hippocampal memory encoding and retrieval: GABAergic control of synaptic plasticity. *Trends Neurosci.* **21**, 273–278 (1998).
66. Iwai, Y., Fagiolini, M., Obata, K. & Hensch, T. K. Rapid critical period induction by tonic inhibition in visual cortex. *J. Neurosci.* **23**, 6695–6702 (2003).
67. Tang, Y., Stryker, M. P., Alvarez-Buylla, A. & Espinosa, J. S. Cortical plasticity induced by transplantation of embryonic somatostatin or parvalbumin interneurons. *Proc. Natl Acad. Sci. USA* **111**, 18339–18344 (2014).
68. Harauzov, A. et al. Reducing intracortical inhibition in the adult visual cortex promotes ocular dominance plasticity. *J. Neurosci.* **30**, 361–371 (2010).
69. Rubenstein, J. L. & Merzenich, M. M. Model of autism: increased ratio of excitation/inhibition in key neural systems. *Genes Brain Behav.* **2**, 255–267 (2003).
This is the first article to propose the hypothesis that a combination of genetic and environmental factors may have an important role in autism through disturbing the balance between excitation and inhibition (increasing E/I ratio).
70. Taylor, M. J. et al. Etiology of autism spectrum disorders and autistic traits over time. *JAMA Psychiatry* **77**, 936–943 (2020).
71. Chen, C. H. et al. Genetic analysis of *GABRB3* as a candidate gene of autism spectrum disorders. *Mol. Autism* **5**, 36 (2014).
72. Feng, J. et al. High frequency of neurexin 1β signal peptide structural variants in patients with autism. *Neurosci. Lett.* **409**, 10–13 (2006).
73. Gauthier, J. et al. Truncating mutations in *NRXN2* and *NRXN1* in autism spectrum disorders and schizophrenia. *Hum. Genet.* **130**, 563–573 (2011).
74. Vaags, A. K. et al. Rare deletions at the neurexin 3 locus in autism spectrum disorder. *Am. J. Hum. Genet.* **90**, 133–141 (2012).
75. Chen, C. H., Lee, P. W., Liao, H. M. & Chang, P. K. Neuroilin 2 R215H mutant mice manifest anxiety, increased prepulse inhibition, and impaired spatial learning and memory. *Front. Psychiatry* **8**, 257 (2017).
76. Prasad, A. et al. A discovery resource of rare copy number variations in individuals with autism spectrum disorder. *G3* **2**, 1665–1685 (2012).
77. Lionel, A. C. et al. Rare exonic deletions implicate the synaptic organizer *gephyrin (GPHN)* in risk for autism, schizophrenia and seizures. *Hum. Mol. Genet.* **22**, 2055–2066 (2013).
78. Shimojima, K. et al. Loss-of-function mutation of *collybistin* is responsible for X-linked mental retardation associated with epilepsy. *J. Hum. Genet.* **56**, 561–565 (2011).
79. Johannesen, K. M. et al. Defining the phenotypic spectrum of *SLC6A1* mutations. *Epilepsia* **59**, 389–402 (2018).
80. Merner, N. D. et al. Regulatory domain or CpG site variation in *SLC12A5*, encoding the chloride transporter *KCC2*, in human autism and schizophrenia. *Front. Cell Neurosci.* **9**, 386 (2015).
81. Carvill, G. L. et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in *CHD2* and *SYNGAP1*. *Nat. Genet.* **45**, 825–830 (2013).
82. Coe, B. P. et al. Neurodevelopmental disease genes implicated by de novo mutation and copy number variation morbidity. *Nat. Genet.* **51**, 106–116 (2019).
83. Rosenfeld, J. A. et al. Genotype-phenotype analysis of *TCF4* mutations causing Pitt-Hopkins syndrome shows increased seizure activity with missense mutations. *Genet. Med.* **11**, 797–805 (2009).
84. Lipton, J. O. & Sahin, M. The neurology of mTOR. *Neuron* **84**, 275–291 (2014).
85. Machado, C. O. et al. Collybistin binds and inhibits mTORC1 signaling: a potential novel mechanism contributing to intellectual disability and autism. *Eur. J. Hum. Genet.* **24**, 59–65 (2016).
86. Kumar, S. et al. Impaired neurodevelopmental pathways in autism spectrum disorder: a review of signaling mechanisms and crosstalk. *J. Neurodev. Disord.* **11**, 10 (2019).
87. Lynch, M. Rate, molecular spectrum, and consequences of human mutation. *Proc. Natl Acad. Sci. USA* **107**, 961–968 (2010).
88. Rodin, R. E. & Walsh, C. A. Somatic mutation in pediatric neurological diseases. *Pediatr. Neurol.* **87**, 20–22 (2018).
89. Krupp, D. R. et al. Exonic mosaic mutations contribute risk for autism spectrum disorder. *Am. J. Hum. Genet.* **101**, 369–390 (2017).
90. Kushima, I. et al. Comparative analyses of copy-number variation in autism spectrum disorder and schizophrenia reveal etiological overlap and biological insights. *Cell Rep.* **24**, 2838–2856 (2018).
91. Poduri, A. et al. Somatic activation of *AKT3* causes hemispheric developmental brain malformations. *Neuron* **74**, 41–48 (2012).
92. Sanders, S. J. et al. Insights into autism spectrum disorder genomic architecture and biology from 71 risk loci. *Neuron* **87**, 1215–1233 (2015).
93. Korb, E. et al. Excess translation of epigenetic regulators contributes to fragile X syndrome and is alleviated by *Brd4* inhibition. *Cell* **170**, 1209–1223 e1220 (2017).
94. Fatemi, S. H., Reutiman, T. J., Folsom, T. D. & Thuras, P. D. GABA_A receptor downregulation in brains of subjects with autism. *J. Autism Dev. Disord.* **39**, 223–230 (2009).
95. Fatemi, S. H. et al. Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. *Biol. Psychiatry* **52**, 805–810 (2002).
96. Hernandez-Herrera, I., Garcia-Perez, R., Sharp, A. J. & Marques-Bonet, T. DNA methylation: insights into human evolution. *PLoS Genet.* **11**, e1005661 (2015).
97. Liu, X. S. et al. Rescue of fragile X syndrome neurons by DNA methylation editing of the *FMR1* gene. *Cell* **172**, 979–992 e976 (2018).
98. Berman, R. F. et al. Mouse models of the fragile X premutation and fragile X-associated tremor/ataxia syndrome. *J. Neurodev. Disord.* **6**, 25 (2014).
99. Atladottir, H. O. et al. Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. *J. Autism Dev. Disord.* **40**, 1425–1430 (2010).
100. Choi, G. B. et al. The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. *Science* **351**, 933–939 (2016).
101. Shin Yim, Y. et al. Reversing behavioural abnormalities in mice exposed to maternal inflammation. *Nature* **549**, 482–487 (2017).
102. Li, Y., Zhou, Y., Peng, L. & Zhao, Y. Reduced protein expressions of cytomembrane GABA_Aβ3 at different postnatal developmental stages of rats exposed prenatally to valproic acid. *Brain Res.* **1671**, 33–42 (2017).
103. Tyzio, R. et al. Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. *Science* **343**, 675–679 (2014).
104. Savardi, A. et al. Discovery of a small molecule drug candidate for selective NKCC1 inhibition in brain disorders. *Chem* **6**, 2073–2096 (2020).
105. Yeo, M. et al. Bisphenol A delays the perinatal chloride shift in cortical neurons by epigenetic effects on the *Kcc2* promoter. *Proc. Natl Acad. Sci. USA* **110**, 4315–4320 (2013).
106. Li, Y. et al. Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. *Cell Stem Cell* **13**, 446–458 (2013).
107. Castro, J. et al. Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett syndrome. *Proc. Natl Acad. Sci. USA* **111**, 9941–9946 (2014).
108. Mellios, N. et al. MeCP2-regulated miRNAs control early human neurogenesis through differential effects on ERK and AKT signaling. *Mol. Psychiatry* **23**, 1051–1065 (2018).
109. Dong, F. et al. Deletion of *CTNNB1* in inhibitory circuitry contributes to autism-associated behavioral defects. *Hum. Mol. Genet.* **25**, 2738–2751 (2016).
110. Mohn, J. L. et al. Adenomatous polyposis coli protein deletion leads to cognitive and autism-like disabilities. *Mol. Psychiatry* **19**, 1133–1142 (2014).
111. Chen, Y., Huang, W. C., Sejourne, J., Clipperton-Allen, A. E. & Page, D. T. *Pten* mutations alter brain growth trajectory and allocation of cell types through elevated β-catenin signaling. *J. Neurosci.* **35**, 10252–10267 (2015).
112. Durak, O. et al. *Chd8* mediates cortical neurogenesis via transcriptional regulation of cell cycle and Wnt signaling. *Nat. Neurosci.* **19**, 1477–1488 (2016).
113. Banerjee, A. et al. Jointly reduced inhibition and excitation underlies circuit-wide changes in cortical processing in Rett syndrome. *Proc. Natl Acad. Sci. USA* **113**, E7287–E7296 (2016).
114. Zhang, W., Peterson, M., Beyer, B., Frankel, W. N. & Zhang, Z. W. Loss of MeCP2 from forebrain excitatory neurons leads to cortical hyperexcitability and seizures. *J. Neurosci.* **34**, 2754–2763 (2014).
115. Kleschevnikov, A. M. et al. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABA_A receptor antagonists. *J. Neurosci.* **32**, 9217–9227 (2012).
116. Costa, A. C. & Grybko, M. J. Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome. *Neurosci. Lett.* **382**, 317–322 (2005).
117. Deidda, G. et al. Reversing excitatory GABA_AR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome. *Nat. Med.* **21**, 318–326 (2015).
This study demonstrates that pharmacological reversal of excitatory GABA action with the NKCC1 blocker bumetanide rescues synaptic and behavioural abnormalities in a mouse model of Down syndrome, indicating that restoration of chloride homeostasis is a promising therapeutic avenue for treating neurodevelopmental disorders.
118. Fernandez, F. et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. *Nat. Neurosci.* **10**, 411–413 (2007).
119. Olmos-Serrano, J. L. et al. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. *J. Neurosci.* **30**, 9929–9938 (2010).
120. Curia, G., Papouin, T., Seguela, P. & Avoli, M. Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. *Cereb. Cortex* **19**, 1515–1520 (2009).
121. Gibson, J. R., Bartley, A. F., Hays, S. A. & Huber, K. M. Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. *J. Neurophysiol.* **100**, 2615–2626 (2008).
122. Centonze, D. et al. Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. *Biol. Psychiatry* **63**, 963–973 (2008).

123. Egawa, K. et al. Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of Angelman syndrome. *Sci. Transl. Med.* **4**, 163ra157 (2012).
124. Sivillia, S. et al. CDKL5 knockout leads to altered inhibitory transmission in the cerebellum of adult mice. *Genes Brain Behav.* **15**, 491–502 (2016).
125. Rein, B. et al. Reversal of synaptic and behavioral deficits in a 16p11.2 duplication mouse model via restoration of the GABA synapse regulator *Npas4*. *Mol. Psychiatry* <https://doi.org/10.1038/s41380-020-0693-9> (2020).
126. Hubner, C. A. et al. Disruption of KCC2 reveals an essential role of K-Cl cotransport already in early synaptic inhibition. *Neuron* **30**, 515–524 (2001). **This study shows that knocking out *Slc12a5* in mice causes severe motor and respiration deficits and is incompatible with life, demonstrating the importance of KCC2 and GABAergic inhibition in the proper development and functioning of the nervous system.**
127. He, Q., Nomura, T., Xu, J. & Contractor, A. The developmental switch in GABA polarity is delayed in fragile X mice. *Eur. J. Neurosci.* **34**, 446–450 (2014).
128. Wang, P. et al. CRISPR/Cas9-mediated heterozygous knockout of the autism gene *CHD8* and characterization of its transcriptional networks in neurodevelopment. *Mol. Autism.* **6**, 55 (2015).
129. Talos, D. M. et al. Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia. *Ann. Neurol.* **71**, 539–551 (2012).
130. Robertson, C. E., Ratai, E. M. & Kanwisher, N. Reduced GABAergic action in the autistic brain. *Curr. Biol.* **26**, 80–85 (2016).
131. Port, R. G. et al. Exploring the relationship between cortical GABA concentrations, auditory gamma-band responses and development in ASD: evidence for an altered maturational trajectory in ASD. *Autism Res.* **10**, 593–607 (2017).
132. Bruining, H. et al. Measurement of excitation–inhibition ratio in autism spectrum disorder using critical brain dynamics. *Sci. Rep.* **10**, 9195 (2020).
133. Goel, A. et al. Impaired perceptual learning in a mouse model of fragile X syndrome is mediated by parvalbumin neuron dysfunction and is reversible. *Nat. Neurosci.* **21**, 1404–1411 (2018).
134. Hashemi, E., Ariza, J., Rogers, H., Noctor, S. C. & Martinez-Cerdeno, V. The number of parvalbumin-expressing interneurons is decreased in the prefrontal cortex in autism. *Cereb. Cortex* **27**, 1931–1943 (2017).
135. Penagarikano, O. et al. Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. *Cell* **147**, 235–246 (2011).
136. Filice, F., Vorckel, K. J., Sungur, A. O., Wöhr, M. & Schwaller, B. Reduction in parvalbumin expression not loss of the parvalbumin-expressing GABA interneuron subpopulation in genetic parvalbumin and shank mouse models of autism. *Mol. Brain* **9**, 10 (2016).
137. Gogolla, N. et al. Common circuit defect of excitatory–inhibitory balance in mouse models of autism. *J. Neurodev. Disord.* **1**, 172–181 (2009).
138. Jung, E. M. et al. *Arid1b* haploinsufficiency disrupts cortical interneuron development and mouse behavior. *Nat. Neurosci.* **20**, 1694–1707 (2017).
139. Vogt, D., Cho, K. K. A., Lee, A. T., Sohal, V. S. & Rubenstein, J. L. R. The parvalbumin/somatostatin ratio is increased in *Pten* mutant mice and by human *PTEN* ASD alleles. *Cell Rep.* **11**, 944–956 (2015).
140. Lauber, E., Filice, F. & Schwaller, B. Prenatal valproate exposure differentially affects parvalbumin-expressing neurons and related circuits in the cortex and striatum of mice. *Front. Mol. Neurosci.* **9**, 150 (2016).
141. Perez-Cremades, D. et al. Alteration of inhibitory circuits in the somatosensory cortex of T665Dn mice, a model for Down’s syndrome. *J. Neural Transm.* **117**, 445–455 (2010).
142. Stoner, R. et al. Patches of disorganization in the neocortex of children with autism. *N. Engl. J. Med.* **370**, 1209–1219 (2014).
143. Yu, F. H. et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. *Nat. Neurosci.* **9**, 1142–1149 (2006).
144. Cheah, C. S. et al. Specific deletion of Na_v1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome. *Proc. Natl Acad. Sci. USA* **109**, 14646–14651 (2012).
145. Spratt, P. W. E. et al. The autism-associated gene *Scn2a* contributes to dendritic excitability and synaptic function in the prefrontal cortex. *Neuron* **103**, 673–685 e675 (2019).
146. Ogiwara, I. et al. Nav1.2 haplodeficiency in excitatory neurons causes absence-like seizures in mice. *Commun. Biol.* **1**, 96 (2018).
147. Yuan, Y. et al. Delayed maturation of GABAergic signaling in the *Scn1a* and *Scn1b* mouse models of Dravet Syndrome. *Sci. Rep.* **9**, 6210 (2019).
148. Torricco, B. et al. Contribution of common and rare variants of the *PTCHD1* gene to autism spectrum disorders and intellectual disability. *Eur. J. Hum. Genet.* **23**, 1694–1701 (2015).
149. Wells, M. F., Wimmer, R. D., Schmitt, L. I., Feng, G. & Halassa, M. M. Thalamic reticular impairment underlies attention deficit in *Ptchd1*^{Y0} mice. *Nature* **532**, 58–63 (2016).
150. Sun, Y. G. et al. GABAergic synaptic transmission triggers action potentials in thalamic reticular nucleus neurons. *J. Neurosci.* **32**, 7782–7790 (2012).
151. Goldman, S. E. et al. Defining the sleep phenotype in children with autism. *Dev. Neuropsychol.* **34**, 560–573 (2009).
152. Young, D. et al. Sleep problems in Rett syndrome. *Brain Dev.* **29**, 609–616 (2007).
153. Han, S. et al. Na_v1.1 channels are critical for intercellular communication in the suprachiasmatic nucleus and for normal circadian rhythms. *Proc. Natl Acad. Sci. USA* **109**, E368–E377 (2012).
154. Fenno, L. E. et al. Comprehensive dual- and triple-feature intersectional single-vector delivery of diverse functional payloads to cells of behaving mammals. *Neuron* **107**, 836–853 (2020).
155. Chao, H. T. et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. *Nature* **468**, 263–269 (2010). **This study demonstrates that knocking out the *Mecp2* gene specifically in GABAergic neurons in the mouse brain partially recapitulates Rett syndrome phenotypes as observed in global *Mecp2*-knockout mice, suggesting the contribution of GABAergic inhibition deficits in the pathogenesis of Rett syndrome.**
156. Ure, K. et al. Restoration of *Mecp2* expression in GABAergic neurons is sufficient to rescue multiple disease features in a mouse model of Rett syndrome. *Elife* **5**, e14198 (2016).
157. Judson, M. C. et al. GABAergic neuron-specific loss of *Ube3a* causes Angelman syndrome-like EEG abnormalities and enhances seizure susceptibility. *Neuron* **90**, 56–69 (2016).
158. Yoo, T. et al. GABA neuronal deletion of *Shank3* exons 14–16 in mice suppresses striatal excitatory synaptic input and induces social and locomotor abnormalities. *Front. Cell Neurosci.* **12**, 341 (2018).
159. Rudolph, S. et al. Cerebellum-specific deletion of the GABA_A receptor δ subunit leads to sex-specific disruption of behavior. *Cell Rep.* **33**, 108338 (2020).
160. Yizhar, O. et al. Neocortical excitation/inhibition balance in information processing and social dysfunction. *Nature* **477**, 171–178 (2011).
161. Hong, W., Kim, D. W. & Anderson, D. J. Antagonistic control of social versus repetitive self-grooming behaviors by separable amygdala neuronal subsets. *Cell* **158**, 1348–1361 (2014).
162. Tropea, D. et al. Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. *Proc. Natl Acad. Sci. USA* **106**, 2029–2034 (2009).
163. Sato, M. & Stryker, M. P. Genomic imprinting of experience-dependent cortical plasticity by the ubiquitin ligase gene *Ube3a*. *Proc. Natl Acad. Sci. USA* **107**, 5611–5616 (2010).
164. Harlow, E. G. et al. Critical period plasticity is disrupted in the barrel cortex of *Fmr1* knockout mice. *Neuron* **65**, 385–398 (2010).
165. He, Q. et al. Critical period inhibition of NKCC1 rectifies synapse plasticity in the somatosensory cortex and restores adult tactile response maps in fragile X mice. *Mol. Psychiatry* **24**, 1732–1747 (2019).
166. Nelson, S. B. & Valakh, V. Excitatory/inhibitory balance and circuit homeostasis in autism spectrum disorders. *Neuron* **87**, 684–698 (2015).
167. Tatavarty, V. et al. Autism-associated Shank3 is essential for homeostatic compensation in rodent V1. *Neuron* **106**, 769–777 e764 (2020).
168. Sinclair, D., Oranje, B., Razzak, K. A., Siegel, S. J. & Schmid, S. Sensory processing in autism spectrum disorders and fragile X syndrome — from the clinic to animal models. *Neurosci. Biobehav. Rev.* **76**, 235–253 (2017).
169. Modi, M. E. & Sahin, M. Translational use of event-related potentials to assess circuit integrity in ASD. *Nat. Rev. Neurol.* **13**, 160–170 (2017).
170. Antoine, M. W., Langberg, T., Schnepel, P. & Feldman, D. E. Increased excitation–inhibition ratio stabilizes synapse and circuit excitability in four autism mouse models. *Neuron* **101**, 648–661 e644 (2019).
171. Guy, J., Gan, J., Selfridge, J., Cobb, S. & Bird, A. Reversal of neurological defects in a mouse model of Rett syndrome. *Science* **315**, 1143–1147 (2007).
172. Mei, Y. et al. Adult restoration of *Shank3* expression rescues selective autistic-like phenotypes. *Nature* **530**, 481–484 (2016).
173. Zeier, Z. et al. Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome. *Gene Ther.* **16**, 1122–1129 (2009).
174. Garg, S. K. et al. Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome. *J. Neurosci.* **33**, 13612–13620 (2013).
175. US National Library of Medicine. ClinicalTrials.gov. <https://clinicaltrials.gov/ct2/show/NCT03872479> (2019).
176. Hilton, I. B. et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. *Nat. Biotechnol.* **33**, 510–517 (2015).
177. Liu, X. S. et al. Editing DNA methylation in the mammalian genome. *Cell* **167**, 233–247 e217 (2016).
178. Qin, L. et al. Social deficits in *Shank3*-deficient mouse models of autism are rescued by histone deacetylase (HDAC) inhibition. *Nat. Neurosci.* **21**, 564–575 (2018).
179. An, D. et al. Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. *Cell Rep.* **21**, 3548–3558 (2017).
180. Pratt, A. J. & MacRae, I. J. The RNA-induced silencing complex: a versatile gene-silencing machine. *J. Biol. Chem.* **284**, 17897–17901 (2009).
181. Sztainberg, Y. et al. Reversal of phenotypes in *MECP2* duplication mice using genetic rescue or antisense oligonucleotides. *Nature* **528**, 123–126 (2015).
182. Kim, J. et al. Patient-customized oligonucleotide therapy for a rare genetic disease. *N. Engl. J. Med.* **381**, 1644–1652 (2019).
183. Griffin, C. E. 3rd, Kaye, A. M., Bueno, F. R. & Kaye, A. D. Benzodiazepine pharmacology and central nervous system-mediated effects. *Ochsner J.* **13**, 214–223 (2013).
184. Henderson, C. et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABA_A receptors with arbaclofen. *Sci. Transl. Med.* **4**, 152ra128 (2012).
185. Stoppel, L. J. et al. R-Baclofen reverses cognitive deficits and improves social interactions in two lines of 16p11.2 deletion mice. *Neuropsychopharmacology* **43**, 513–524 (2018).
186. Berry-Kravis, E. M. et al. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. *Nat. Rev. Drug Discov.* **17**, 280–299 (2018).
187. Kharod, S. C., Kang, S. K. & Kadam, S. D. Off-label use of bumetanide for brain disorders: an overview. *Front. Neurosci.* **13**, 310 (2019).
188. Delpire, E. et al. Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: development of a highly selective and more potent in vitro probe. *Bioorg. Med. Chem. Lett.* **22**, 4532–4535 (2012).
189. Gagnon, M. et al. Chloride extrusion enhancers as novel therapeutics for neurological diseases. *Nat. Med.* **19**, 1524–1528 (2013).
190. Cardarelli, R. A. et al. The small molecule CLP257 does not modify activity of the K⁺-Cl⁻ co-transporter KCC2 but does potentiate GABA_A receptor activity. *Nat. Med.* **23**, 1394–1396 (2017).
191. Gagnon, M. et al. Reply to the small molecule CLP257 does not modify activity of the K⁺-Cl⁻ co-transporter KCC2 but does potentiate GABA_A receptor activity. *Nat. Med.* **23**, 1396–1398 (2017).
192. de Los Heros et al. The WNK-regulated SPAK/OSR1 kinases directly phosphorylate and inhibit the K⁺-Cl⁻ co-transporters. *Biochem. J.* **458**, 559–573 (2014).
193. Kahle, K. T., Rinehart, J. & Lifton, R. P. Phosphoregulation of the Na-K-2Cl and K-Cl cotransporters by the WNK kinases. *Biochim. Biophys. Acta* **1802**, 1150–1158 (2010).
194. Moore, Y. E., Deeb, T. Z., Chadchankar, H., Brandon, N. J. & Moss, S. J. Potentiating KCC2 activity is sufficient to limit the onset and severity of seizures. *Proc. Natl Acad. Sci. USA* **115**, 10166–10171 (2018).

195. McCamphill, P. K. et al. Selective inhibition of glycogen synthase kinase 3 α corrects pathophysiology in a mouse model of fragile X syndrome. *Sci. Transl. Med.* **12**, eaam8572 (2020).
196. O'Leary, H. M. et al. Placebo-controlled crossover assessment of mecamermin for the treatment of Rett syndrome. *Ann. Clin. Transl. Neurol.* **5**, 323–332 (2018).
197. Vahdatpour, C., Dyer, A. H. & Tropea, D. Insulin-like growth factor 1 and related compounds in the treatment of childhood-onset neurodevelopmental disorders. *Front. Neurosci.* **10**, 450 (2016).
198. Glaze, D. G. et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. *Neurology* **92**, e1912–e1925 (2019).
199. Hnisz, D., Shrinivas, K., Young, R. A., Chakraborty, A. K. & Sharp, P. A. A phase separation model for transcriptional control. *Cell* **169**, 13–23 (2017).
200. Feng, Z., Chen, X., Zeng, M. & Zhang, M. Phase separation as a mechanism for assembling dynamic postsynaptic density signalling complexes. *Curr. Opin. Neurobiol.* **57**, 1–8 (2019).
201. Lai, A., Valdez-Sinon, A. N. & Bassell, G. J. Regulation of RNA granules by FMRP and implications for neurological diseases. *Traffic* **21**, 454–462 (2020).
202. Zeng, M. et al. Reconstituted postsynaptic density as a molecular platform for understanding synapse formation and plasticity. *Cell* **174**, 1172–1187 e1116 (2018).
203. Rapanelli, M. et al. Behavioral, circuitry, and molecular aberrations by region-specific deficiency of the high-risk autism gene *Cul3*. *Mol. Psychiatry* <https://doi.org/10.1038/s41380-019-0498-x> (2019).
204. Lu, J. et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. *Chem. Biol.* **22**, 755–763 (2015).
205. Delpire, E. & Weaver, C. D. Challenges of finding novel drugs targeting the K-Cl cotransporter. *ACS Chem. Neurosci.* **7**, 1624–1627 (2016).
206. Tang, X. et al. Pharmacological enhancement of *KCC2* gene expression exerts therapeutic effects on human Rett syndrome neurons and *Mecp2* mutant mice. *Sci. Transl. Med.* **11**, eaau0164 (2019). **This study reports the discovery of the first group of small-molecule compounds that enhance *KCC2* gene expression using human neuron and mouse models of Rett syndrome to demonstrate the therapeutic efficacy of identified compounds in rescuing neural circuit and behaviour phenotypes.**
207. Han, S. et al. Autistic-like behaviour in *Scn1a*^{-/-} mice and rescue by enhanced GABA-mediated neurotransmission. *Nature* **489**, 385–390 (2012).
208. Han, S., Tai, C., Jones, C. J., Scheuer, T. & Catterall, W. A. Enhancement of inhibitory neurotransmission by GABA_A receptors having α 2,3-subunits ameliorates behavioral deficits in a mouse model of autism. *Neuron* **81**, 1282–1289 (2014).
209. Lemonnier, E. et al. A randomised controlled trial of bumetanide in the treatment of autism in children. *Transl. Psychiatry* **2**, e202 (2012).
210. Lemonnier, E. et al. Treating fragile X syndrome with the diuretic bumetanide: a case report. *Acta Paediatr.* **102**, e288–e290 (2013).
211. Sprengers, J. J. et al. Bumetanide for core symptoms of autism spectrum disorder (BAMBI): a single center, double-blinded, participant-randomized, placebo-controlled, phase-2 superiority trial. *J. Am. Acad. Child Adolesc. Psychiatry* **50890-8567**, 31290–31299 (2020).
212. Castrop, H. & Schiesl, I. M. Physiology and pathophysiology of the renal Na-K-2Cl cotransporter (NKCC2). *Am. J. Physiol. Ren. Physiol.* **307**, F991–F1002 (2014).
213. Williams, J. R., Sharp, J. W., Kumari, V. G., Wilson, M. & Payne, J. A. The neuron-specific K-Cl cotransporter, KCC2. Antibody development and initial characterization of the protein. *J. Biol. Chem.* **274**, 12656–12664 (1999).
214. Chen, B. et al. Reactivation of dormant relay pathways in injured spinal cord by KCC2 manipulations. *Cell* **174**, 1599 (2018).
215. Takayanagi, Y. et al. Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice. *Proc. Natl Acad. Sci. USA* **102**, 16096–16101 (2005).
216. Leonzino, M. et al. The timing of the excitatory-to-inhibitory GABA switch is regulated by the oxytocin receptor via KCC2. *Cell Rep.* **15**, 96–103 (2016).
217. Tyzio, R. et al. Maternal oxytocin triggers a transient inhibitory switch in GABA signaling in the fetal brain during delivery. *Science* **314**, 1788–1792 (2006).
218. Andari, E. et al. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. *Proc. Natl Acad. Sci. USA* **107**, 4389–4394 (2010).
219. Yatawara, C. J., Einfeld, S. L., Hickie, I. B., Davenport, T. A. & Guastella, A. J. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. *Mol. Psychiatry* **21**, 1225–1231 (2016).
220. Xiao, L., Priest, M. F., Nasenbeny, J., Lu, T. & Kozorovitskiy, Y. Biased oxytocinergic modulation of midbrain dopamine systems. *Neuron* **95**, 368–384 e365 (2017).
221. Sgritta, M. et al. Mechanisms underlying microbial-mediated changes in social behavior in mouse models of autism spectrum disorder. *Neuron* **101**, 246–259 e246 (2019).
222. Buffington, S. A. et al. Microbial reconstitution reverses maternal diet-induced social and synaptic deficits in offspring. *Cell* **165**, 1762–1775 (2016).
223. Gong, X. et al. An ultra-sensitive step-function opsin for minimally invasive optogenetic stimulation in mice and macaques. *Neuron* **107**, 38–51.e8 (2020).
224. Wang, W. et al. Chemogenetic activation of prefrontal cortex rescues synaptic and behavioral deficits in a mouse model of 16p11.2 deletion syndrome. *J. Neurosci.* **38**, 5939–5948 (2018).
225. Qin, L., Ma, K. & Yan, Z. Chemogenetic activation of prefrontal cortex in *Shank3*-deficient mice ameliorates social deficits, NMDAR hypofunction, and Sgk2 downregulation. *iScience* **17**, 24–35 (2019).
226. Larimer, P., Spatazza, J., Stryker, M. P., Alvarez-Buylla, A. & Hasenstaub, A. R. Development and long-term integration of MGE-lineage cortical interneurons in the heterochronic environment. *J. Neurophysiol.* **118**, 131–139 (2017).
227. Hunt, R. F., Girsakis, K. M., Rubenstein, J. L., Alvarez-Buylla, A. & Baraban, S. C. GABA progenitors grafted into the adult epileptic brain control seizures and abnormal behavior. *Nat. Neurosci.* **16**, 692–697 (2013).
228. Martinez-Losa, M. et al. Nav1.1-overexpressing interneuron transplants restore brain rhythms and cognition in a mouse model of Alzheimer's disease. *Neuron* **98**, 75–89 e75 (2018).
229. Brock, J., Brown, C. C., Boucher, J. & Rippon, G. The temporal binding deficit hypothesis of autism. *Dev. Psychopathol.* **14**, 209–224 (2002).
230. Chiken, S. & Nambu, A. High-frequency pallidal stimulation disrupts information flow through the pallidum by GABAergic inhibition. *J. Neurosci.* **33**, 2268–2280 (2013).
231. Hao, S. et al. Forniceal deep brain stimulation rescues hippocampal memory in Rett syndrome mice. *Nature* **526**, 430–434 (2015).

Acknowledgements

This work was funded by a Bridge to Independence Award from the Simons Foundation Autism Research Initiative awarded to X.T., US National Institutes of Health (NIH) grant R01 MH104610 awarded to R.J., and NIH grant R01 MH085802 and a grant to the Simons Center for the Social Brain from the Simons Foundation Autism Research Initiative awarded to M.S. The authors also thank C. Clairmont for his substantial help with revising the manuscript, and X. Jing, M. Enriquez, K. Cruite, M. Gallagher, D. Tomasello, E. Wogram and E. Majercak for useful comments and discussions.

Author contributions

X.T. researched data for the article. All authors contributed equally to discussion of content, writing and reviewing or editing of the manuscript.

Competing interests

R.J. is a cofounder of Fate Therapeutics, Fulcrum Therapeutics and Omega Therapeutics.

Peer review information

Nature Reviews Neuroscience thanks A. Contractor, V. Martinez Cerdeño, Z. Yan and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© Springer Nature Limited 2021